Theme	Sub-theme

1. Views on smoking	1.1 Hostility towards smoking

3. Reasons to quit smoking	3.1 To improve health

3.2 Social stigma

3.3 Saving money

3.4 Personal

4. Emotions connected with smoking initiation	4.1 Regret starting

6. Beliefs that influence quit attempts	6.1 Control of nicotine dependence

6.2 Motivation and willpower

6.3 Confidence

7. Difficulties quitting/cutting down	7.4 Lack of motivation

8. Goals	8.1 Smoking cessation

9. Methods used to quit smoking	9.1 Abrupt

9.2 Cut down first

10. Methods of cutting down	10.1 Not smoking as many cigarettes

10.2 Not smoking in the morning

10.3 Smoking only part of the cigarette

11. Non-medical aids to quit smoking	11.1 Distraction

11.2 Motivation

11.3 Exercising

12. Reasons for using NRT	12.1 To aid quit attempt

12.4 To help with cravings

12.5 Rid of habit

15. Factors to encourage use of NRT	15.1 Free samples

15.2 Aid quit attempt

16. Use of NRT	16.2 Incorrect use/underuse

17. Length of NRT use	17.1 Short-term

17.2 Long-term

18. Knowledge about NRT	18.1 Current regulations

19. Concerns about NRT	19.1 Addiction

19.2 Harmful when used long-term

19.3 Effective

19.4 Health consequences

19.5 Delays quitting process

22. Helpfulness of NRT	22.1 Recommend

23. Recommendation of cessation aids	23.2 Other forms of therapy

24. Stop smoking services	24.1 Advantages

24.2 Disadvantages


2q23.1 deletion syndrome	SMS431*

Developmental delay	+

Motor delay	+

Language impairment	+

Behavioral problems	+

Autistic-like symptoms	+

Sleep disturbances	+

Repetitive behaviors (stereotypies)	+

Self-injurious behaviors	+

Short attention span	+

Aggression	+

Seizures	+

Infantile hypotonia	+

Infantile feeding difficulties	+

Eye abnormalities	+

Heavy arched eyebrows	-

Prominent nose	-

Thin upper lip	+

Widely spaced teeth	-


Parameter	Measured and calculated values

Ash weight (g)	376.33

Char weight (g)	752.67

Tar weight (g)	73.58

Syngas flow rate (Nm3/hr)	16.02

Fuel consumption rate (kg/hr)	6.37

Gas yield (Nm3/kg)	2.51

Cold gas efficiency (%)	60.37

Mass conversion efficiency (%)	89.98

Carbon conversion efficiency (%)	91.18


Age (years)	Day of cycle before GnRHa therapy	Stage of endometriosis

(a) Tissue for DIGE assay (n = 4)

33	15	IV

27	16	IV

27	18	IV

37	27	III

(b) Tissue for WB assay (n = 10)

33	10	IV

25	14	IV

32	17	IV

29	13	III

27	15	IV

26	13	III

29	15	IV

23	11	IV

39	9	IV

36	12	III


Age and gender	Population-at-risk	Annual incidence (per 100,000 person-years) 2002–2014

Odontoid fractures	Hangman's fractures	Atypical fractures	Total

Men <70	201,402	1.0	0.4	0.5	1.9

Women <70	201,444	0.5	0.2	0.03	0.8

Men ≥70	28,713	15.8	0.8	1.3	17.9

Women ≥70	41,382	16.0	1.1	0.7	17.8

Total	472,941	3.0	0.4	0.4	3.8


	40-49	50-69	Total (40-69)

Women invited	56,888	63,552	120,440

Observed one-year participation rate	32.6%	30.6%	31.6%

Estimated one-year participation rate	37.1%	35.1%	36.1%

Observed two-year participation rate	55.1%	50.3%	52.5%

Estimated two-year participation rate	59.6%	54.8%	57.0%


Inhibitors	Target	Anti‐CSC activity

Tenovin‐6	SIRT1/2	CML, AML

BDF4‐1, ‐2a, ‐2b, ‐2d	SIRT1/2	Colon, glioblastoma

AGK2	SIRT2	Glioblastoma

Salermide	SIRT1/2	Colorectal

Inhibitors	Target	Anticancer activity

Nicotinamide	SIRT1/2/3/5/6	Leukemia, oral, prostate

Sirtinol	SIRT2	Breast, lung, prostate, oral

Salermide	SIRT1/2	Lung, breast, colon

JGB‐1741	SIRT1	Breast

Cambinol	SIRT1/2/5	Burkitt lymphoma

EX527	SIRT1	Leukemia

AC‐93253	SIRT1/2/3	Prostate, pancreas, lung

Inauhzin	SIRT1	Lung, colon

Tenovin‐1	Unknown	Burkitt lymphoma, melanoma


	Female: egg or central cell	Male: pollen or sperm	F1progeny	F1progeny

	CHX	CHX	CHX	Expect	Obs

	17	18	19	17	18	19	17	18	19	(%)	(%)

a	–	+	–	–	+	–	–/–	+/+	–/–	50	62 (95)

	–	+	–	–	–	–	–/–	+/–	–/–	50	3 (5)

b	–	+	–	–	+	–	–/–	+/+	–/–	50	98 (70)

	–	–	–	–	+	–	–/–	+/–	–/–	50	41 (30)

c	–	–	+	–	–	+	–/–	–/–	+/+	50	92 (97)

	–	–	+	–	–	–	–/–	–/–	+/–	50	3 (3)

d	–	–	+	–	–	+	–/–	–/–	+/+	50	69 (75)

	–	–	–	–	–	+	–/–	–/–	+/–	50	23 (25)


Factor	MPT ≥9 s n (%)	MPT <9 s n (%)	Significance

Method of RLN reconstruction

 Direct anastomosis	33 (94.3)	2 (5.7)	N.S.

 Ansa cervicalis-RLN anastomosis	152 (86.9)	23 (13.1)

 Free nerve grafting	12 (80.0)	3 (20.0)

VCP preoperatively

 Yes	92 (88.5)	12 (11.5)	N.S.

 No	108 (87.5)	16 (12.9)

Site of distal anastomosis

 Outside	146 (87.4)	21 (12.6)	N.S.

 Inside	54 (88.5)	7 (11.5)


 	 	Movements from	Movements to

 	Na	Total	With haulier	%b	Total	With haulier	%

Premises type

Small-pig producer	1755	3888	108	3%	1927	211	11%

Non-assured commercial producers	285	6277	3550	57%	1232	798	65%

QHA producers	290	12237	9973	81%	4019	3601	90%

Slaughterhouse	29	2	0	0%	14105	8448	60%

Market	13	682	259	38%	1858	892	48%

Showground	8	20	0	0%	22	0	0%

Ferry collection centres	2	63	62	98%	6	2	33%

Scottish Regions

Highlands and Islands	677	2690	821	31%	2058	274	13%

Mid Scotland and Fife	185	1464	562	38%	1311	166	13%

Scotland Central Belt	229	1994	901	45%	5134	3904	76%

South Scotland	428	3538	1810	51%	2337	841	36%

East Scotland	514	12872	9618	75%	8471	5639	67%

English Regions

Yorkshire and The Humber	70	30	21	70%	371	351	95%

North East England	105	175	32	18%	1501	1362	91%

North West England	83	256	84	33%	660	470	71%

West Midlands	13	5	0	0%	31	22	71%

East Midlands	21	46	27	59%	685	458	67%

East of England	29	12	3	25%	585	460	79%

South East England	5	0	0	0%	7	1	0%

South West England	10	6	4	67%	7	2	29%

Northern Ireland	-	63	62	98%	6	2	33%

Wales	8	8	3	38%	4	0	0%

Other countries	-	10	4	40%	1	0	0%


Strains	No. of plants inoculated	Infection rate (%)	Wilt indexa

Fusarium solani CFD-1	160	96.3	3.6

Fusarium oxysporum CFD-1	144	97.9	3.7


Covariate	Multivariate analysis hazard ratio	p value

Sex, male versus female	0.87 (0.23–3.29)	0.837

Age at revision	1.02 (0.96–1.08)	0.497

Body mass index	1.05 (0.93–1.18)	0.461

Revision indication

 Pseudotumor versus	1.00	Baseline

 Fracture	0.21 (0.31-1.40)	0.106

 Other	0.31 (0.49–1.90)	0.203

Type of revision

 Femoral only with metal-on-metal bearing versus all component revision with nonmetal-on-metal bearing	5.65 (1.08–29.4)	0.040


Variable	Sulpiride	Placebo	p-value

Mean (SD)	Mean (SD)

Participant characteristics

 Age (years)	24.58 (4.19)	23.92 (4.70)	0.717

 Body mass index (kg/m2)	24.56 (1.45)	24.32 (3.57)	0.832

 Education (years)	15.92 (1.45)	14.92 (2.78)	0.289

 Raven’s matrices (percentile)	88.00 (16.69)	86.08 (15.68)	0.774


	Control Group Individuals (n = 32)	Intervention Group Individuals (n = 37)	Unadjustedsignificance	Adjusted for highest qualification at baseline

Individual Domain	Mean baseline	Mean follow-up	Mean baseline	Meanfollow-up	Coefficient	P value	Coefficient	P value

i) Finding relevant literature	6.42	6.89	6.00	7.59	0.72	0.16	0.87	0.10

ii) Critically reviewing the literature	6.03	6.72	5.78	6.69	-0.33	0.95	0.25	0.61

iii) Using a computer referencing system (eg Endnote)	4.52	5.22	3.47	4.71	0.59	0.38	0.54	0.43

iv) Writing a research protocol	4.06	4.39	3.67	5.69	1.42	< 0.05*	1.76	< 0.05*

v) Securing research funding	2.90	3.29	2.75	4.70	1.53	< 0.05*	1.46	< 0.05*

vi) Submitting an ethics application	3.48	3.47	3.58	6.10	2.38	< 0.001**	2.37	< 0.001**

vii) Designing questionnaires	5.00	5.67	4.39	5.96	0.61	0.38	0.86	0.23

viii) Collecting data e.g. surveys, interviews	5.58	6.72	5.53	7.00	0.22	0.76	0.42	0.57

ix) Using computer data management systems	4.16	5.22	3.71	4.68	-0.39	0.93	0.11	0.81

x) Analysing qualitative research data	4.39	5.47	2.97	5.10	1.14	< 0.1†	1.27	< 0.05*

xi) Analysing quantitative research data	3.94	5.17	3.67	4.39	-0.54	0.38	-0.40	0.53

xii) Writing a research report	4.45	4.39	4.00	5.18	0.96	< 0.1†	1.28	< 0.05*

xiii) Writing for publication in peer-reviewed journals	3.81	4.00	3.14	4.80	1.15	< .0.05*	1.04	< 0.1†

xiv) Integrating research findings into practice	6.34	7.11	6.28	6.76	-0.27	0.67	-0.18	0.79

xv) Providing advice to less experienced researchers	6.67	3.76	3.00	4.93	1.22	< 0.05*	1.23	< 0.05*

Total score	4.65	5.19	4.13	5.63	0.98	< 0.05*	1.11	< 0.05*


Characteristics	Number (n)	*Percent (%)

Age group of women (years)

15-19	1933	17.5

20-29	6770	61.3

30-49	2336	21.2

Missing	[141]

Parity

0	3811	35.7

1	2155	20.2

2-4	3210	30.1

≥5	1492	14.0

Missing	[512]

Singleton/Multiple

Singleton	9696	95.6

Multiple	451	4.4

Missing	[1033]

Occupation of mother

Salaried employee/business	1062	20.6

Subsistence farmer	1215	23.5

Housewife	2886	55.9

Missing	[6017]

Mbarara	3916	35.0

Bushenyi	3510	31.4

Ibanda	1045	9.3

Isingiro	936	8.4

Kiruhura	905	8.1

Other districts	868	7.8

Name of health facility attended

Comboni hospital	636	5.7

Ibanda hospital	1803	16.1

Ishaka Adventist hospital	1435	12.8

Kitagata hospital	1098	9.8

Mbarara regional referral hospital	5731	51.3

Rushere Community hospital	477	4.3


	Structured Care (31) 	Care-As-Usual (11) 	P -value

Yearly check performed by (%)

 General practitioner	29.0	36.4	0.65

 Practice nurse	51.6	63.6	0.49

 Practice assistant	6.5	0	0.39

 Diabetes specialist nurse	3.2	0	0.55

 GP with PN/PA	9.7	0	0.28

Tri-monthly checks performed by (%)

 General practitioner	16.1	9.1	0.57

 Practice nurse	61.6	63.6	0.89

 Practice assistant	22.6	27.3	0.75

Insulin treatments provided by (%)

 Internist	6.5**	63.6**	<0.001

 General practitioner	61.3	36.4	0.15

 Practice nurse	16.1	18.2	0.88

 Diabetes specialist nurse	67.7**	18.2**	0.005

Consultation between healthcare professionals (%)

 General practitioner	100*	80.0*	0.02

 Practice nurse	71.4	70.0	0.93

 Practice assistant	46.4	40.0	0.73

 Diabetes specialist nurse	78.6**	30.0**	0.005

 Dietician	50.0*	10.0*	0.03

Estimated percentage of patients that received education

 Diet % (sd)	86.7 (17.9)	83.5 (28.7)	0.91

 Exercise % (sd)	89.6 (16.0)	76.0 (29.5)	0.17

 Smoking behavior % (sd)	90.0 (11.4)	73.3 (44.2)	0.17

 Foot examination % (sd)	89.3 (17.0)	69.5 (38.3)	0.14

Education on diet, exercise, foot examination or smoking behavior.

 by DSN (%)	35.0*	0.0*	0.04

 by GP (%)	61.3	81.8	0.24

 by PN/PA (%)	87.1	90.0	0.74

Diabetes passport, often or always used in practice (%)	78.6*	40.0*	0.05


Plant part	Use	Use form	Percentage of users	Management

Stem	Mescal production	Whole stems are backed inside an earthen pit, grounded, fermented and distilled	100	Extraction of whole individuals from wild populations

Flower buds	Food	Flowering buds are boiled or roasted, coocked with eggs or hot chilli sauce	66	People extract the whole scape, to get the flowering buds

Floral scape	Roasted over the fire while working in the field	33	Extract the young whole floral scape

Leaf bases	Food	People ask for the backed leave bases to the mescal producer and eat them as candy	30	Leave bases remaining from mescal production

Medicine	An infusion of cooked agave leaf for lung affections	10

Applying a piece of fresh leaf (or roasted) directly to wounded area	33	Eventually cutting up one leaf

Floral escape	Fodder	Cattle eat the growing scape	40	Cattle eat the early floral scape while it is starting to grow

Construction	Used in small fences	16	Extract the whole floral scape

Whole plant	Religious	Agaves are transplanted from the wild to “little mountains” (montecitos) dedicated to the GuadalupeVirgin	10	Each year in December small agave individuals are transplanted from wild populations to home gardens

Uses of Mescal	As medicine	A small glass of mezcal aliviate the stomach-ache, flu symptoms, fever and cold- weat	30	(produced from agave stems)

Ritual	A small glass of mezcal is offered to the death in the “ofrendas de muertos”	80


Author	Mean (m) or median (M) follow-up (mo)	PSM	Local or distant recurrence

Rogers [9]	15.7 (m)	0	No

Dogra [10]	29.4 (m)	0	No

Nazemi [15]	4 (M)	0	No

Hemal [17]	8.3 (m)	NR	No

Abaza [12]	15.4 (m)	0	No

Klingler [3]	NR	0	NR

Lorenzo [13]	12 (M)	0	No

White [14]	10.5 (m)	NR	NR

Boger [16]	NR	NR	NR

Rogers [11]	NR	NR	NR


Localisation	Gland	Type

Lips	Upper lip	Serous

	Lower lip	Serous

Cheek	Buccal mucosa	Mixed (predominantly mucous)

	Parotid	Serous

Hard palate	Postero-lateral hard palate	Mucous

Tongue	Von Ebner (dorsal)	Serous

	Weber Blandin Nuhn (marginal)	Mixed (predominantly mucous)

Floor of mouth	Submandibular	Mixed (predominantly serous)

	Sublingual	Mixed (predominantly mucous)


MRI finding	PCNSL	GBM	p-value

Localization	only supratentorial	66.7%	98.1%	<0.001

only infratentorial	5.5%	1.9%	0.308

supra- and infratentorial	27.7%	0%	<0.001

Type of lesions	solitary demarcated lesion	3.7%	13%	0.046

solitary infiltrative type	20.4%	51.9%	0.121

multiple infiltrative lesions	51.9%	35.2%	0.081

diffuse infiltrative type	24.1%	0%	<0.001

Type of enhancement	homogeneous	64.8%	0%	<0.001

nonhomogeneous	14.8%	98.1%	<0.001

diffuse infiltrative – worm-like, patchy, stripy...	20.4%	0%	<0.001

presence of necrosis	5.6%	88.9%	<0.001

Involvement of brain surface	without reaching brain surface	12.9%	11.1%	0.567

reaching brain surface	87%	88.9%	0.846

meningeal infiltration	35.2%	46.3%	0.240

ependymal infiltration	53.7%	37%	0.054

Optic nerves, chiasma or tracts involvement	42.6%	5.6%	<0.001

Cranial nerves involvement (optical nerves and tracts excluded)	5.6%	0%	0.079

Corpus callosum infiltration	42.6%	44.4%	0.846

Butterfly pattern	24.1%	14.8%	0.224

Basal ganglia involvement	55.6%	18.5%	<0.001

Cerebral cortex involvement	83.3%	51.9%	<0.001

aDWI	free diffusion	1.9%	10.4%	0.189

restricted diffusion in some part of the solid	97%	89.6%	0.189

Signs of bleeding	5.6%	44.4%	<0.001

Presence of vasogenic edema	92.6%	83.3%	0.139


Sequencing results	Number of total raw reads	60,866,926

 	Number of total clean reads	51,606,364

 	Number of total clean nucleotides (nt)	4,644,572,760

 	Q20 percentage of total clean reads	95.92%

 	GC percentage of total clean nucleotides	51.26%

 	N percentage of total clean nucleotides	0.00%

Assembling results	Number of unigenes	38,504 (5,372 into distinct clusters; 33,132 singletons)

 	Total length (nt) of total unigenes	21,977,286

 	Mean length (nt) of total unigenes	571

 	N50 (nt) of total unigenes	711

Annotation	Unigenes with Nr database	25,456 (66% of 38,504 unigenes)

(E-value < =1e-5)	Unigenes with Nt database	20,554 (53%)

 	Unigenes with Swiss-Prot database	17,651 (46%)

 	Unigenes with KEGG database	16,622 (43%), 257 pathways

 	Unigenes with COG database	7,204 (19%), 25 functional categories

 	Unigenes with GO database	16,588 (43%), 62 subcategories grouped to 3 main categories

 	Biological process	27 sub-categories

 	Cellular component	17 sub-categories

 	Molecular function	18 sub-categories

 	Total unigenes annotated	26,650 (69% of 38,504 unigenes)


		"gold standard" = result of sentinel node biopsy

		occult metastatic disease: Yes	occult metastatic disease: No

new predictive marker for occult metastatic disease (ECAD)	Low ECAD	true positive	false positive	all test positives

	expression	a	b	a + b

	High ECAD	c	d	all test

	expression	false negative	true negative	negatives

				c + d

		a + c	b + d

		all with occult	all without occult

		disease	disease


Gases	Training Set	Unlabeled Set	Test Set

Carbon monoxide	116	116	116

Toluene	132	132	132

Formaldehyde	253	253	253

All-3	501	501	501


Clinical features	Mean ± SD, n (%)

Age	66.5 ± 8.0

Weight	73.2 ± 8.5

Body mass index	27.8 ± 2.6

Gender

Male	12 (60)

Female	8 (40)

Smoking	9 (45)

Diseases

Hypertension	17 (85)

Heart failure	3 (15)

Diabetes	10 (50)

Medication

Organic nitrates	0 (0)

Aspirin	20 (100)

Beta-blockers	14 (70)

Angiotensin inhibitors	9 (45)

Calcium channel blockers	5 (25)

Hypolipidaemics	13 (65)


Cell type	Action	References

Langerhans cells	Activate and proliferate Treg cells in resting state; limit activation of Treg cells in presence of pathogen	[116]

Induce Treg cells favoring flora tolerance with limited antigens presentation	[117]

Induce Treg cells by secretion of IL-10 and TGF-β	[118]

Memory Treg cells	Localize to hair folliclesNon-migratory and non-responsive in normal skinProliferate and produce IL-17 in inflamed skin	[119]

Are activated, proliferated and differentiated into potent suppressorAttenuate autoimmune reactions in tissues upon repeated responses to antigens	[120]

Macrophages	Promote expression of the chemokine CCL22Induce migration and activation of Treg cells	[121]

Express M2-like TIM-4hiCD169+Act immunoregulatory function and promote engraftment of cardiac allografts	[122]

Mast cells	Act as intermediate at Treg cells dependent allograft tolerance via IL-9	[123]

Counteract Treg cell function through IL-6 and OX40/OX40L axis toward Th17 cell differentiation	[124]

Dermal dendritic cells	Are capable of antigen capture and presentation to CD4+ T cells and Treg cells generation	[125]

Dermal regulatory cells	Induce Treg cells through PD-1 engagement with expression of ABCB5+ molecules	[126]

Dermal fibroblasts	Induce proliferation of natural Treg cells with IL-15	[127]

Dermal stromal cells	Express CD90+ and induce Tregs cells	[128]


t-statistic and p-values for correlation significance

t-statistics

	Sig	NN

Sig

NN	2.917

NNSig	2.969	0.052

p-values

	Sig	NN

Sig

NN	0.998

NNSig	0.998	0.521


Generated Commands	Description

Start	SLAM and control algorithms begin

Stop	Stops robot's movements but the SLAM algorithm continues

Turn to the left	Sustained command to make the robot turning to user's left

Turn to the right	Sustained command to make the robot turning to user's right

Exit	SLAM stops and a map is visualized


Variable	Odds ratio (95% CI), P Value

Before accounting for confounding by indicationa	After accounting for confounding by indication

Methicillin-sensitive S. aureus carrier	0.5 (0.3, 1.0), 0.03	0.4 (0.2, 0.8), 0.01

Intubation	4.7 (1.8, 12.3), 0.002	5.3 (2.0, 14.4), 0.001

Fluoroquinolone	1.9 (1.2, 3.0), 0.01	-

Aminoglycoside	-	0.3 (0.1, 0.7), 0.003

Days from ICU admission to negative swab	< .0001	< .0001

1	1.0, reference	1.0, reference

2	2.0 (1.2, 3.3)	2.2 (1.3, 3.7)

≥ 3	15.6 (8.4, 29.0)	19.6 (10.4, 37.1)

Chronic liver disease	-	4.1 (1.2, 13.6), 0.02


 	Everolimus 1.5 mg (n = 61)	MMF 2 g (n = 61)

Recipient characteristics

Age (years)

 Mean ± standard deviation	42.5 ± 14.13	38.6 ± 11.36

 Median (range)	42.0 (18 to 65)	36.0 (20 to 64)

Gender, n (%)

 Male	46 (75.4)	37 (60.7)

 Female	15 (24.6)	24 (39.3)

Body mass index (kg/m2)

 Mean ± standard deviation	22.46 ± 4.03	21.79 ± 2.78

 Median (range)	21.97 (15.5 to 37.5)	21.09 (16.0 to 27.6)

Primary disease leading to transplantation, n (%)

 Glomerulonephritis/glomerular disease	16 (26.2)	9 (14.8)

 Polycystic disease	3 (4.9)	3 (4.9)

 Hypertension/nephrosclerosis	5 (8.2)	2 (3.3)

 Diabetes mellitus	3 (4.9)	5 (8.2)

 Interstitial nephritis	2 (3.3)	0 (0.0)

 Obstructive disorder/reflux	6 (9.8)	3 (4.9)

 IgA nephropathy	11 (18.0)	16 (26.2)

 Unknown	8 (13.1)	16 (26.2)

 Other	7 (11.5)	7 (11.5)

Current dialysis

 None	12 (19.7)	8 (13.1)

 Hemodialysis	42 (68.9)	48 (78.7)

 Peritoneal dialysis	7 (11.5)	5 (8.2)

HLA mismatches

 1	7 (11.5)	2 (3.3)

 2	9 (14.8)	16 (26.2)

 3	25 (41.0)	24 (39.3)

 <3	16 (26.2)	18 (29.5)

 ≥3	45 (73.8)	43 (70.5)

Donor characteristics

Mean ± standard deviation age (years)	52.3 ± 8.99	55.2 ± 8.23

Deceased heart beating, n (%)	1 (1.6)	0 (0.0)

Deceased nonheart beating, n (%)	0 (0.0)	1 (1.6)

Living related, n (%)	36 (59.0)	43 (70.5)

Living unrelated, n (%)	24 (39.3)	17 (27.9)


Metabolite	Number of neighbors	P value

Reporter metabolites (up)

Glutathione [c]	10	6.0E-05

UDP-glucose [c]	11	3.1E-04

D-galactose [e]	6	2.5E-03

Alpha,alpha-trehalose 6-phosphate [c]	4	3.7E-03

Alpha,alpha-trehalose [c]	4	6.0E-03

Alpha-D-glucose 6-phosphate [c]	8	8.2E-03

Oxidized glutathione [c]	4	6.6E-03

CDP-diacylglycerol [m]	4	8.6E-03

Alpha-D-glucose [c]	23	2.2E-02

D-glucose 1-phosphate [c]	6	1.2E-02

Reporter metabolites (down)

AMP [c]	42	5.4E-09

ATP [c]	83	1.1E-08

5-phospho-alpha-D-ribose 1-diphosphate [c]	15	2.5E-06

L-glutamine [c]	17	6.6E-06

L-histidine [c]	7	8.2E-05

L-aspartate [c]	12	8.7E-05

CO2 [m]	10	1.3E-04

Isocitrate[m]	5	2.5E-04

Phosphate [c]	49	8.5E-05

Glycine [m]	4	9.6E-04


Treatment	Belief	N	Recommendations	N	Adherence	N	Challenges to Adherence

Blood pressure	Believes blood pressure affects PKD	16	Prescribed blood pressure medication	16	Number of days per week when remember to take medication:		• Believes diet and exercise are better than drugs• Forgets when feeling well• Forgets when rushed, busy, or tired

<7 days/week	4

7 days/week	12

Exercise	Believes exercise or physical activity affects PKD	14	Told to avoid certain types of exercise or physical activity	11	Does not adhere to recommendations to avoid certain exercises of physical activity	2	• Activity helps mentally• Disagrees with recommendations (that exercise is harmful)

Diet	Believes diet affects PKD	16	Told to follow certain diets	15	Adherence to low-salt diet:		• Absence of or conflicting recommendations• Affects social aspects of eating• Difficult to measure

 • By non-physician sources	10	Does not add salt to food	12

Avoids salty food	4

Does not eat out/Cooks own meals	4

Water Intake	Believes drinking a lot of water affects PKD	10	Told to drink “a lot of water”	12	Adheres to recommendations	10	• Frequent urination• Experiences symptoms• Difficult to develop habit

 • By non-physician sources	3	Does not adhere to recommendations	1

Uncertain	5	Uncertain but tries to adhere to recommendations	5


Metric	Questions	Average	Standard

		response	deviation

Overall usability	1–19	6.02	1.04

System usefulness	1–8	6.13	0.93

Information quality	9–15	5.66	1.20

Interface quality	16–18	6.24	0.99


Functional traits	Interpretation

Calvin–Benson cycle	CO2 fixation

Utilization of various carbon sources	Adaptation to the diverse organic matter in sponge mesohyl

Anaerobic respiration	Energy supply in anoxic environment

Denitrification	Energy supply in anoxic environment

Sulfate reduction	Energy supply in anoxic environment

Peptidase	Compensation for the reduced amino acid synthesis capacity

Endospore formation	Resistance to environmental threats; widespread distribution

Metal resistance	Resistance to environmental threats

Antibiotic resistance	Competition in symbiotic communities; resistance to environmental threats

Eukaryotic-like proteins	Host–microbe recognition

Type II secretion system	Interaction with host environment

Widespread Colonization Island	Tight adhesion

Type VI secretion system	Host–microbe interaction, microbe–microbe competition


Procedures	References	Detergents	Detergent concentrations (C)	Ultrasound treatment (S)1)	Homogenization (H)2)	Filtration (F)

1	S.B. Singh-Verma (1968), LR. Bakken (1985)	Sodium hexametaphosphate	C1) 0,2% (w/v)	S1) 40 W, 60 sec, 5 impulses/sec (different repetitions)	H1) none	F1 none

 	 	C2) 0,5% (w/v)	S2) 65 W, 60 sec, 5 impulses/sec (different repetitions)	H2) 60 sec, speed 5 (different repetitions)	F2) 12–15 μm filter

2	S.B. Singh-Verma (1968), LR. Bakken (1985)	Bromhexine hydrochloride	C1) 0,2% (w/v)	S1) 40 W, 60 sec + 65 W, 60 sec, 5 impulses/sec	H1) none	n.a.

 	 	 	 	H2) 2× 60 sec, speed 5

3	W.B. Yoon and R.A. Rosson (1990)	Tween	C1) 5 μg/ml	S1) 15 W, 30 sec, 5 impulses/sec	H1) none	n.a.

 	 	C2) 10 μg/ml	S2) 35 W, 30 sec, 5 impulses/sec	H2) 5 min, speed 5

 	 	C3) 25 μg/ml

4	E.L Schmidt (1974)	Tween 80 + 0.007 g ml-1 flocculation reagent (Ca (OH)2: MgCO3 (2:5))	C1) 25 μl/ml	n.a.	n.a.	n.a.

5	O. Resina-Pelfort et al. (2003)	Triton X-100	C1) 10 μg/ml	S1) 35 W, 30 sec, 5 impulses/sec	H1) none	n.a.

 	 	C2) 20 μg/ml	S2) 45 W, 30 sec, 5 impulses/sec	H2) 5 min, speed 5

6	L R. Bakken (1985)	Sodium pyrophosphate	C1) 0,2% (w/v)	S1 3× 40 W, 60 sec, 5 impulses/sec	H1) 3× 60 sec, speed 5	n.a.


Programme, Country	Water Frequency 1	Fruit Juices Frequency 2	Soft Drinks Frequency 2

VIASANO, Belgium	4 (4–5)	6 (4–6)	4 (2–5)

Healthy kids in Bulgaria, Bulgaria	6 (5–6)	4 (3–5)	2 (1–4)

EPODE Flandre Lys, France	4 (4–5)	6 (4–6)	3 (2–5)

Paideiatrofi, Greece	5 (5–6)	4 (4–5)	1 (1–2)

MAIA, Portugal	5 (4–6)	4 (2–4)	2 (1–3)

SETS, Romania	5 (5–6)	4 (3–5)	2 (2–4)

JOGG Zwolle, The Netherlands	4 (3–4)	3 (2–5)	3 (2–6)

Total	5 (4–6)	4 (3–6)	2 (1–4)


Authors 	Results

Gavini et al. [25]	Ion-implanted instruments reached significantly higher cycle numbers before fracture compared to annealed and non-implanted files.

Wolle et al. [26]	Argon II improved the performance of S1 files moderately, whereas nitrogen ion-implanted files performed worse in the fatigue test.


Cause of corneal opacification	Eyes

Posttrauma	25

Postcorneal ulcer	20

Glaucoma	4

Unknown	4


GenBank accession no.	Original name	Country

HQ591366	PCV2 , isolate 90-08-21	Croatia, 2008

HQ591367	PCV2, isolate 110-08-2	Croatia, 2008

AY256460	PCV2, strain 375	Hungary, 2003

AY424405	PCV2, isolate AUT5	Austria, 2003

HQ591368	PCV2, isolate 126-07-5	Croatia, 2007

HQ591369	PCV2, isolate 147-07-7	Croatia, 2007

HQ591370	PCV2, isolate 161-08-2	Croatia, 2008

HQ591365	PCV2, isolate 70-08-2	Croatia, 2008

AY180397	PCV2, strain Pingtung-5	Taiwan, 2002

AY484410	PCV2, isolate NL-control-4	Netherlands, 2003

AF311296	BFDV	Australia, 2000

AF071879	PCV1	SAD, 1998

GU930366	PRRSV, isolate Hun06	Hungary, 2009

AY035960	PRRSV, isolate 361-4	Denmark, 1994

JQ043210	PRRSV, 174-07-1	Croatia, 2007

DQ324711	PRRSV, isolate Prz-87	Poland, 2005

JQ043212	PRRSV, isolate 660-07-2	Croatia, 2007

JQ043213	PRRSV, isolate 1152-08-10	Croatia, 2008

AY035976	PRRSV, strain 2567/96	Italy, 1996

AY035961	PRRSV, isolate 48/92-1	Denmark, 2001

AY035975	PRRSV, isolate 2481/97	Denmark, 2001

M96262	Lelystad virus	Netherlands, 1991

JQ043211	PRRSV, 177-07-2-1	Croatia, 2007

GU930368	PRRSV, isolate Hun08	Hungary, 2009

DQ324708	PRRSV, strain Okt-46	Belarus, 2004

DQ324719	PRRSV, strain Soz-6	Belarus, 2004

DQ324727	PRRSV, strain Yuz-34	Belarus, 2004

EU071271	PRRSV, strain KR	Russia, 2007

AF438362	PRRSV, strain Aus	Lithuania, 2000

DQ324701	PRRSV, strain Bor-41	Belarus, 2004

DQ324702	PRRSV, strain Bor-54	Belarus, 2004

L39363	PRRSV, isolate IL1	United States, 1996

L39362	PRRSV, isolate IA6	United States, 1996

U18750	PRRSV, isolate ISU-3927	United States, 1996


Variable	No. patients (n = 41)*	Median expression Survivin DeltaEx3	AD	p

FIGO stage

IB	0 (8)	0	0	0.59

IIB	2 (16)	0.09	24.51

IIIB	2 (17)	0.11	35.68

Histology of tumors

Squamous cell	2 (34)	0.01	16.99	0.04

Adenocarcinoma	2 (5)	0.22	60.12

Adenosquamous	0 (2)	0	0

Menopause

Pre-Menopause	2 (10)	0.14	48.94	0.33

Menopause	1 (8)	0.02	10.65

Post-Menopause	1 (23)	0.01	14.99


	Independent association with increasing RANKL expression (Pvalue)	Independent association with increasing RANK expression (Pvalue)

Diagnosis during pregnancy (yes vs. no)	<0.001	0.67

Tumor size (≤2 cm vs. >2 cm)	0.23	0.87

Nodal involvement (negative vs. positive)	0.15	0.19

Histological grade (I vs. II vs. III)	0.09	0.7

Breast cancer subtypes (luminal A vs. luminal B vs. HER2 vs. triple negative)	0.75	<0.001

Increasing progesterone receptor expression by IHC (continuous variable)	<0.001	0.17

Neoadjuvant chemotherapy (yes vs. no)	0.69	<0.001


Overall ranking scale (on a scale from 1–10)

Question: In the last two days of care, how well did the doctors, nurses and other professional staff...	Average

Provide medical care that respected his/her wishes?	8.2

Make sure that [patient] died with dignity – that is died on her/his own terms?	8.2

Make sure [patient’s] symptoms were controlled to a degree acceptable to her/him?	8

Communicate with patient and family about the illness and likely outcomes of care?	7.3

Provide emotional support for you and [patient’s] family and friends?	6.8

What number would you give the overall care that [patient] received in the last two days of life?	7.7

Scale score	7.7

Comparison of Domain Scores (range: 0 to 1)

Advance care planning	0.10

Coordination	0.16

Focus on individual	0.271

Informing & decision making	0.301

Attend to family	0.511


	General CVRM networks	Specific CVRM networks

Mean	SD	Min	Max	Mean	SD	Min	Max

Density	0.38	0.17	0.08	0.83	0.37	0.22	0	0.83

Number of high frequency contacts	8.87	5.64	0	20	10.65	8.24	0	33

Centrality of CVRM coordinator	6.61	3.38	2.00	16	7.07	4.97	0	24

Homophily on SBP targets	0.60	0.43	−0.42	1.00	0.55	0.46	−0.46	1.00

Homophily on LDL targets	0.53	0.49	−0.87	1.00	0.52	0.52	−0.87	1.00


Code	Alkali Treatment	Silane Coupling Agent	Volume Fraction of Fiber Vf (vol %)

PA1010	-	-	-

HF	-	-	20

HF-S1	NaOH	S1 (Aminosilane)	20

HF-S2	NaOH	S2 (Epoxysilane)	20

HF-S3	NaOH	S3 (Ureidosilane)	10, 20, 30


Purification step	Total fused peptide (mg)	Total p53pAnt (mg)	Purity (%)	Yield (%)

Total protein extract	n.d	n.d	43*	100

Inclusion bodies	n.d	n.d	79*	-

First affinity chromatography	184**	43	90*	-

Precipitation recovery	184	43	-	100*

Thrombin cleavage	-	-	-	95*

Second affinity chromatography	-	34**	95	85*


Variables	Chlorhexidine	Placebo	Dry cord

Hospital data	(n = 86)	(n = 86)	(n = 75)

 Age of mother (years, mean ± SD)	23.87 ± 2.54	23.77 ± 2.86	25.12 ± 3.24

 Vaginal delivery	100.0	100.0	100.0

 Male births	48.8	64.0	58.7

 Birth weight (grams, mean ± SD)	2728.3 ± 479.5	2684.3 ± 453.6	2794.8 ± 437.6

 No. of pelvic examinations (mean ± SD)	2.37 ± 1.25	2.07 ± 1.00	2.00 ± 0.97

Problems during delivery

 Meconium staining	2.3	2.3	5.3

 Prolonged labor	2.3	1.2	1.3

Maternal risk factors for infection

 LPVb > 24 h	4.7	2.3	2.7

Chorioamnionitis	0.0	0.0	0.0

 Fever in mother	1.2	0	1.3

 Maternal UTI	0.0	0.0	1.3

Time since birth (hrs:min, mean ± SD)	4:39 ± 2.31	4:35 ± 2:49	4:12 ± 2:37

Community data	(n = 36)	(n = 24)	(n = 19)

Age of mother (years, mean ± SD)	24.42 ± 3.95	24.62 ± 4.13	25.79 ± 3.91

Male births	38.9	50.0	52.6

Did the person clean hands before conducting delivery	97.2	100.0	100.0

New razor blade for cutting the cord	100.0	95.8	100.0

Baby given bath immediately after delivery	94.4	100.0	100.0


Characteristics	Frequency n = 82	Percent (%)

<underline>Age</underline>(years)	Mean Age =27.6, SD =4.5

16–20	6	7.3

21–25	22	26.8

26–30	37	45.1

31–35	12	14.6

36-40	5	6.1

<underline>Marital Status</underline>

Married	76	92.7

Single	1	1.2

Cohabiting	2	2.4

No response	3	3.7

<underline>Occupation</underline>

Employed	16	19.5

Student	8	9.8

Civil servant	2	2.4

Unemployed	8	9.8

Artisan	14	17.1

Trading	32	39

No response	2	2.4

<underline>Educational attainment</underline>

Primary	9	10.9

JSS	21	25.6

SSS	11	13.4

Poly technique	21	25.6

University	15	18.3

No response	5	6.1

<underline>Religion</underline>

Christianity

Islam	34

48	41.5

58.5

<underline>Ethnic group</underline>

Yoruba	72	87.8

Igbo	6	7.3

No response	4	4.8


miR ID	Present result	Previous report	Type of sample	Reference

hsa-miR-106b-5p	↑	↓	Brain	[13]

hsa-miR-181b-5p	↓	↓	Brain, lymphoblastoid cell line	[13,16]

hsa-miR-195-5p	↑	↑	Lymphoblastoid cell line	[15]

hsa-miR-19b-3p	↑	↓	Lymphoblastoid cell line	[14]

hsa-miR-320a	↓	↓	Lymphoblastoid cell line	[14]

hsa-miR-328	↓	↓	Brain	[13]

hsa-miR-663a	↓	↑	Lymphoblastoid cell line	[14]


Cell Line	Tumor Type	NOTCH1 Mutation	Effect on NOTCH1 Signaling	Reference

KOPT-K1	T-LL	L1600P/del(P)*	Gain	 [3]

REC-1	MCL	del(ECN1)/del(P)*	Gain	this paper/ [7]

MAVER-1	MCL	None	N.A.	 [7]

HCC1599	Breast Carcinoma	del(ECN1)	Gain	 [10]

MB-157	Breast Carcinoma	del(ECN1)	Gain	Unpublished data

HCC1587	Breast Carcinoma	None	N.A.	 [10]


Assessment1	Telehone interview	Baseline visit	3 month visit	6 month visit	12 month visit	24 month visit

AD patient

Inclusion criteria	X

Demographics, diagnoses, drugs		X

CDR		X				X

MMSE		X			X	X

Verbal flow, clock drawing test		X	X	X	X	X

MNA		X

Weight, BMI		X	X	X	X	X

Mobility and balance tests by Guralnik		X	X	X	X	X

FIM		X	X	X	X	X

NPI		X		X

Grip strength, blood pressure, heart rate		X	X	X	X	X

Cornell depression scale		X			X

Falls and fractures			X	X	X	X

Use of health and social services, admission to permanent institutional care, mortality			X	X	X	X

Spousal caregiver

Demographics, diagnoses, drugs		X

Zarit burden scale		X			X	X

GDS		X			X

RAND-36 QOL		X			X	X

Mobility and balance tests by Guralnik		X			X

Use of health and social services, mortality			X	X	X	X


Gender	Age	Age at onset	Evidence for a diagnosis of epilepsy	MRI

EEG	Other features	Treatment response

M	70	66	Non-specific bilateral temporal lobe slowing	Oroalimentary automatisms, gustatory hallucinations	Complete	Normal

M	62	54	L temporal epileptiform	Oroalimentary automatisms	Complete	Normal

M	68	65	Non-specific L temporal slowing	No	Complete	Normal

M	72	71	Non-specific R temporal slowing	Déjà vu	Complete	Bilateral high T2 signal in hippocampus

M	68	62	Bilateral (L more marked) mid-anterior temporal sharp and slow-wave epileptiform	Oroalimentary automatisms; brief unresponsiveness	Complete	Normal

M	76	65	Non-specific bilateral temporal slowing	Olfactory hallucinations	Complete	Normal

M	66	56	Normal	Olfactory hallucinations; brief unresponsiveness	Complete	Normal

M	64	61	Bilateral temporal epileptiform	Olfactory hallucinations; oroalimentary automatisms	Complete	Normal

M	63	59	Normal	No	Complete	Normal

M	76	73	Normal	Oroalimentary automatisms; brief unresponsiveness	Complete	Normal

F	60	55	Non-specific bilateral temporal slowing	Brief unresponsiveness	Complete	Normal


level of convergence	phenotype	organism	references

nucleotide

coding mutations in several genes	rate of proliferation in a novel host and at higher temperature	X174 virus	[21]

Gly119Ser in ace-1	organophosphate resistance	seven insect species	[22,23]

gene

pykF and nadR	rate of proliferation in a glucose-limited medium	Escherichia coli	[24]

yellow	wing spot	Drosophila tristis and Drosophila biarmipes	[25]

protein accumulation profile

proteins regulated by guanosine tetraphosphate	rate of proliferation in a glucose-limited medium	E. coli	[26]

molecular pathway

RNA polymerase complex	rate of proliferation at high temperature	E. coli	[14]

organ

compound eye	sensitivity to light	certain annelids, arrow worms, insects	[7]

behaviour and organs

no sound production and flat wings	no sound production, protection against parasitoids	criquets	[27]

feeding behaviour and habitat adaptations	ecology and body morphology	lizards	[28]


Maize gene	Intron TE insertion(s)	Maize gene length (Kb)	Sorghum ortholog gene length (Kb)

ZmTti1	2 Kb hobo DNA transposon	20.87	12.1

ZmTti2	6 Kb Gypsy LTR retrotransposon	9.1	4.2

ZmATM	2.2 Kb L1/CIN4 retrotransposon	131	71

	2.1 Kb L1/CIN4 retrotransposon

	1.7 Kb L1/CIN4 retrotransposon

	3.1 Kb Ty1/Copia retrotransposon

	1.2 Kb Ty1/Copia retrotransposon

ZmATR	2.4 Kb Gypsy LTR retrotransposon	45	31

	10.2 Kb Gypsy LTR retrotransposon

	3 Kb Ty1/Copia retrotransposon

	4.7 Kb Ty1/Copia retrotransposon

ZmSMG1	1.4 Kb Ty1/Copia retrotransposon	30	22.6

	2.1 Kb L1/CIN4 retrotransposon

ZmTOR	2 Kb L1/CIN4 retrotransposon	51	31.8

	5 Kb Ty1/Copia retrotransposon


ICD-10 Code	# of patients	Prescribed Antibiotic	Cases that needed antibiotic	Cases that needed + received antibiotics	Appropriate prescription rate (%)	Adequate prescription rate (%)

J00	581	17	14	1	82.36	7.14

J01	93	70	4	4	5.71	100

J02	306	157	9	5	3.18	2.94

J03	166	138	16	15	11.59	93.75

J04	34	12	0	0	–	–

J05	8	0	0	0	–	–

J06	191	117	0	0	0	0

J10	0	0	0	0	–	–

J11	0	0	0	0	–	–

H65	8	6	2	2	33.33	100

H66	6	6	6	6	100	100

Total	1393	523	51	33	9.75	64.70


G grade	Number of tumor samples

CD146 expression

Low/absent	incomplete high	complete high

1		3

2	4	3	12

3	2	9	7

4			1

total	6	15	20


	Base model	Effect modification model

OR	95%CI	OR	95%CI

SNAP participation (ref = eligible non-participants)	2.02	1.44-2.83	2.09	1.48-2.95

Age (years)	1.02	1.01-1.03	1.02	1.01-1.03

Gender (ref = female)	0.45	0.30-0.67	0.45	0.30-0.67

Race/ethnicity (ref = Non-Hispanic white)

 Non-Hispanic black	2.79	1.45-5.38	2.76	1.43-5.32

 Hispanic	2.15	1.30-3.56	2.12	1.28-3.51

 Other	1.46	0.64-3.35	1.42	0.62-3.26

Marital status (ref = married)

 Cohabitating, not married	1.12	0.70-1.81	1.11	0.69-1.79

 Single	0.94	0.67-1.32	0.93	0.66-1.31

Working status (ref = yes)	0.96	0.70-1.32	0.95	0.69-1.32

Mental health (ref = not having a mental health problem)	1.53	0.93-2.50	1.54	0.94-2.52

Neighborhood poverty category (ref = not poor)

 Poor	1.18	0.78-1.80	1.16	0.76-1.77

 Very poor	1.02	0.67-1.57	1.01	0.66-1.55

Density unhealthy food outlets	1.01	0.98-1.03	1.00	0.97-1.03

SNAP participation* Density unhealthy food outlets			1.02	0.99-1.05


RADIODENCITY OF BONE GRAFTS	At 7th day follow-up	At 1st month follow-up	At 6 months follow-up	At 1 year follow-up

	No. of pts.	%	No. of pts.	%	No. of pts.	%	No. of pts.	%

GOOD	178	100	171	96.1	162	91.0	147	82.6

PARTIAL	00	00	03	1.7	09	5.1	17	9.5

LUCENT	00	00	04	2.2	07	3.9	14	7.9

Total	178	100.0	178	100.0	178	100.0	178	100


	1st visitFebruary 2012	2nd visitApril 2012	Last visit before starting dialysis June 2014

Weight (kg)	84,3	82,9	76

BMI (kg/m2)	29	28	25

eGFR (mL/min/1,73 m2)	19	16	12

P-Urea (mmol/L)	28,8	18,3	24,4

P-Creatinine (μmol/L)	389	401	777

P-Phosphate (mmol/L)	1,3	1,3	1,4

P-Potassium (mmol/L)	3,6	3,8	4,0

P-Albumin (g/L)	38	39	38

Pt(U)-Urea (mmol/d)		205 = 47 g protein	162 = 40 g protein


Subject number	Region of interest	H&E staining	APP staining

Sheep 01	AL	Normal	0

AR	Normal	1

BL	Normal	0

BR	Microglial activation	2

C	Focal hemorrhagic necrosis	2

D	Normal	0

Sheep 03	AL	Normal	0

AR	Normal	0

BL	Normal	0

BR	Normal	0

C	Normal	0

D	Small perivascular petechial hemorrhage	1

Sheep 04	AL	Normal	0

AR	Normal	0

BL	Normal	0

BR	Small perivascular petechial hemorrhage at edge, artifact?	0

C	Small perivascular petechial hemorrhage at edge, artifact?	0

D	Normal	0

Sheep 05	AL	Normal	0

AR	Normal	0

BL	Normal	0

BR	Normal	0.5

C	Normal	0

D	Normal	0

Sheep 06	AL	Localized focus of acute meningitis and SAH in depth of sulcus	0

AR	Normal	0

BL	Normal	0

BR	Normal	0

C	Focal hemorrhage near deep gray nuclei	2

D	Normal	0

Sheep 07	AL	Normal	0

AR	Normal	0

BL	Normal	0

BR	Normal	0

C	Normal	0

D	Normal	0


Recipient	No. of embryos transferred	No. offetuses	Days of gestation	Fetal fibroblast cell lines	Mono-allelic cell lines (%)	Bi-allelic cell lines (%)

R725	205	6	26	F1, F2, F3, F4, F5, F6	F3, F4, F5(50.0)	F1, F2(33.3)

R801	181	2	29	F7, F8	-(0%)	-(0%)


SVMs Models With Different Input Variable	Mean Absolute Percentage Error (MAPE) (%)

(a) Rebound Hammer (RH) Test	8.92%

(b) Ultrasonic Pulse Velocity (UPV) Test	9.25%

(c) SonReb (RH+UPV) Test	6.77%


Province	Area (Hectares)	National Percentage	Province	Area (Hectares)	National Percentage

Agusan del Norte	244.98	0.1	Leyte	5,807.07	2.26

Aklan	1,144.44	0.45	Maguindanao	907.92	0.35

Albay	1,081.17	0.42	Marinduque	2,732.22	1.06

Antique	945.9	0.37	Masbate	5,302.08	2.06

Aurora	497.07	0.19	Metropolitan Manila	39.69	0.02

Basilan	7,641.18	2.97	Misamis Occidental	2,066.49	0.8

Bataan	238.59	0.09	Misamis Oriental	341.19	0.13

Batangas	508.95	0.2	Negros Occidental	4,393.26	1.71

Biliran	231.39	0.09	Negros Oriental	2,004.93	0.78

Bohol	9490.5	3.69	Northern Samar	4,286.52	1.67

Bulacan	391.14	0.15	Occidental Mindoro	1,842.93	0.72

Cagayan	5,175.27	2.01	Oriental Mindoro	2,975.31	1.16

Camarines Norte	3,628.17	1.41	Palawan	5,6261.3	22.23

Camarines Sur	5,315.31	2.07	Pampanga	251.73	0.1

Camiguin	4.95	0	Pangasinan	1,206.63	0.47

Capiz	1,999.8	0.78	Quezon	14,170	5.51

Catanduanes	1,671.3	0.65	Romblon	792.45	0.31

Cavite	35.73	0.01	Samar	10,140.6	3.94

Cebu	2,893.77	1.13	Sarangani	92.61	0.04

Compostela Valley	130.14	0.05	Shariff Kabunsuan	1,018.89	0.4

Davao del Norte	195.57	0.08	Siquijor	70.2	0.03

Davao del Sur	361.53	0.14	Sorsogon	3,895.74	1.52

Davao Oriental	1975.5	0.77	South Cotabato	13.86	0.01

Dinagat Islands	1654.56	0.64	Southern Leyte	643.68	0.25

Eastern Samar	5,595.93	2.18	Sultan Kudarat	949.95	0.37

Guimaras	577.08	0.22	Sulu	2,0564.8	8

Ilocos Norte	127.53	0.05	Surigao del Norte	11867	4.62

Ilocos Sur	228.87	0.09	Surigao del Sur	5,642.55	2.19

Iloilo	1,322.91	0.51	Tawi-Tawi	11,322.2	4.4

Isabela	592.29	0.23	Zambales	981.54	0.38

La Union	144.18	0.06	Zamboanga del Norte	1,961.82	0.76

Lanao del Norte	1,580.94	0.61	Zamboanga del Sur	9,501.66	3.7

Lanao del Sur	620.37	0.24	Zamboanga Sibugay	13,889.2	5.4


Marker	D number	Primer sequences (5’>3’)	Annealing temperature (°C)	Product size (bp)

ATA29H01 	D12S1048	GGTCTGCTTAGGTCCCTTTT 	55	209-229

 	 	AAGGAACCAAGGAGTGGAAG

Mfd75A 	D12S59	CTCACTCATGCTTGTTTTGA 	60.3	164-179

 	 	GATCACGTCAGACTGGGCT

AFM092wd11 	D12S331	TAACATTTATTCATCTCCATACTGA 	57.8	175-181

 	 	ACATGTAAGAGAGNAAGTTTACAAA

AFM296yg5 	D12S345	CAGCCTGGGTAACAAA 	57.8	209-238

 	 	AGCAATGTGTGCATTC

UT8102 	D16S689	GCCTGGGCGATAAGTGAGA 	56	209

 	 	TCACCACAACCCAAACATTC

AFM156xb8 	D16S3026	CTCCCTGAGCAACAAACACC 	55	178-210

 	 	GGTCATTTATATGCGCCTGA

AFMa306yf1 	D16S3063	AGCTTGTTTTAGCAANAATTTC 	59	218-260

 	 	TGCCTGATTCCACCAA

AFM342xd9	D16S3121	CATGTTGTACATCGTGATGC 	58	79-85

 	 	AGCTTTTATTTCCCAGGGGT


Gene	Forward	Reverse

EP1	5′-ATGGTGGGCCAGCTTGTC-3′	5′-GCCACCAACACCAGCATTG-3′

EP2	5′-TCCTTGCCTTTCACGATTT-3′	5′-AGAGCTTGGAGGTCCCATT-3′

EP3	5′-TGGTCTCCGCTCCTGATAA-3′	5′-TGCATTCTTTCTGCTTCTCC-3′

EP4	5′-TGCTCTTCTTCAGCCTGTCC-3′	5′-GAGCTACCGAGACCCATGTT-3′

FP	5′-TCTGGTCTGTGCCCACTTC-3′	5′-GACTCCAATACACCGCTCAAT-3′

PGT	5′-CTGGTGGATTTCATTAAACGG-3′	5′-GGCTGCTGAGGTGCCATAC-3′

MRP4 total	5′-AAAGTGCCAAAGTAATCCAGC-3′	5′-GTTCAAAGCCACAGAATCCA-3′

MRP4 variant 1	5′-CGGGCATACAAAGCAGAA-3′	5′-GGACCCAAAGGCAACG-3′


Technique	Comments

PRECONTRAST

Dark blood stacks typically in axial, coronal and sagittal planes e.g. HASTE	Provides vessel wall imaging as well as complementary information to CE-MRA regarding lumen

Noncontrast bright blood stack(s) e.g. SSFP

 	CONTRAST

3D contrast-enhanced magnetic resonance angiography e.g. spoiled gradient echo	Appropriate vasculature should be covered depending on clinical questions and known or suspected diagnosis (see Table 2)

 	POSTCONTRAST

T1-weighted vessel wall imaging e.g. VIBE or FAME	Additional vessel wall imaging, particularly useful to delineate thickening and thrombus

 	CARDIAC ACQUISITIONS

Multiplane cine imaging e.g. SSFP Aortic valve velocity-encoded cine Myocardial imaging: T2 precontrast, T1W early post contrast, late post-gadolinium imaging	May be appropriate when aortic root disease involves the aortic valve or when myocardial inflammation is suspected, particularly in small-vessel vasculitides


Gene symbol	Gene name	Log2FC (P/M)	FDR

Igj	Immunoglobulin joining chain	8.6779562	2.29E-11

Ly6c2	Lymphocyte antigen 6 complex, locus C2	12.30121239	2.92E-09

Slfn4	Schlafen 4	15.5668286	1.75E-06

Lcn2	Lipocalin 2	7.312076677	3.37E-05

Slpi	Secretory leukocyte peptidase inhibitor	12.73813718	5.33E-05

Ccdc126	Coiled-coil domain containing 126	−8.341365207	0.000225043

Atp5g3	ATP synthase, H+ transporting, mitochondrial F0 complex, subunit C3 (subunit 9)	−11.69540624	0.000280756

Fsd1l	Fibronectin type III and SPRY domain containing 1-like	−6.703008314	0.000462131

Dnajc12	DnaJ heat shock protein family	−14.11777559	0.000618267

Rbm8a	RNA binding motif protein 8a	−11.28615955	0.001526552

Fat3	FAT atypical cadherin 3	−14.08641235	0.003575335

Col3a1	Collagen, type III, alpha 1	14.61654737	0.003584831

Akap17b	A kinase (PRKA) anchor protein 17B	−10.53057236	0.009607167

Cysltr1	Cysteinyl leukotriene receptor 1	−14.65367542	0.009752316

Sgip1	SH3-domain GRB2-like (endophilin) interacting protein 1	−6.380242524	0.011651515

Pou2af1	POU domain, class 2, associating factor 1	9.055182034	0.019402858

Dnm1	Dynamin 1	−12.9307709	0.050431759


Variable	Baseline	6 months

Energy (Kcal)	2225 ± 1109	1589 ± 384 **

Carbohydrate (g)	273 ± 194	199 ± 74 *

Protein (g)	98 ± 36	78 ± 23 *

Fat (g)	84 ± 39	55 ± 18 **

Starch (g)	148 ± 48	114 ± 36 *

Sugar (g)	121 ± 171	74 ± 64

Non-starch polysaccharide (g)	18 ± 5	14 ± 3 **

Saturated fatty acids (g)	30 ± 16	20 ± 6 **

Monounsaturated fatty acids (g)	29 ± 12	19 ± 7 **

Polyunsaturated fatty acids (g)	16 ± 8	10 ± 4 **


Species	Volume (μL)	Mycotoxin	Extraction Procedure	Detection Technique	LOD (μg/L)	LOQ (μg/L)	Reference

Single mycotoxin

Human	50	OTA	LLE: CH2Cl2	ELISA vs. CE-LIF (CE/laser-induced FD)	0.5	-	[39]

Human	-	OTA	IAC	HPLC-FD	-	-	[42]

Human	-	OTA	SPE: Sep-Pak RP-18. IAC: Ochraprep	HPLC-FD	0.1	0.4	[44]

Human	-	OTA	LLE: CHCl3/HCl	HPLC-FD	0.05	-	[35]

Human	2000	OTA	LLE: CHCl3	HPLC-FD LC-ESI-MS/MS	0.01	0.07	[36]

Human	6000	OTA	SPE: C18	HPLC-FD	0.1	0.2	[41]

Human	1000	OTA	LLE: CHCl3, SPE	HPLC-FD	0.05	-	[37]

Human	2000–3000	OTA	LLE: CHCl3, IAC: Ochraprep	ELISA and HPLC-FD	-	0.050	[38]

Human	-	OTA	IAC: Ochraprep	HPLC-FD	-	0.1	[43]

Human	-	AFB1	IAC: Easi-Extract Aflatoxin	ELISA	-	-	[50]

Rat	100	ZON	LLE: TBME	LC-MS/MS	-	0.5	[48]

Rat	100	ZON	LLE: TBME	HPLC-FD	-	10	[49]

Swine	800	OTA	LLE: CH2Cl2	HPLC	0.1	-	[40]

Chicken	250	DON	LLE: ACN	LC-MS/MS	0.1–0.2	1	[46,47]

Horse	2000	OTA	LLE: CH2Cl2, IAC: Ochratest	ELISA, HPLC-FD	0.015	-	[21]

Multi-mycotoxin

Human	500	OTA, OTα	LLE: CHCl3/isopropanol	HPLC-FD	0.05	0.1	[58]

Chicken	20–250	EN B, EN B1	LLE: ACN	LC/MS/MS, UHPLC-HRMS	0.000091–0.00017	0.025	[45]

Pig	250	EN A, A1, B, B1	LLE: ACN	LC-MS/MS	0.01–0.001	0.1–0.2	[52,53]

Pig	250	DON, T-2, HT-2, OTA, FB1, AFB1, ZON, ZAN, α-ZOL, β-ZOL, α-ZAL, β-ZAL, DOM-1	LLE: ACN	LC-MS/MS	0.01–0.52	0.5–10	[51,54]

Chicken, pig, laying hens, turkey poults	250	ZON, α-ZOL, β-ZOL, ZAN, α-ZAL, β-ZAL	LLE: ACN	LC–MS/MS (U)HPLC–HR-MS	0.004–0.07	0.2–5	[55,57]

Chicken, Pig	250	DON, 3-ADON, 15-ADON, DOM-1	LLE: ACN	LC–MS/MS	0.01–0.7	0.1–2	[56]

Fish	250	AFB1, AFB2, AFG1, AFG2, OTA, FUS-X, STG, FB1, FB2, FB3, BEA, EN A, EN A1, EN B, EN B1	DLLME: ACN/EtOAc	LC/MS/MS	0.1–12.0	1.5–17.0	[59]


Product/active ingredient(s)	Formulation	Country of origin*	2005 availability (n = 29)	Named in the top 3 sellers in 2005 (n = 28)	Mean selling price 2005†

1. artemether/lumefantrine	20/120 mg tablets, co-formulated	Switzerland	21 (72.4%)	5 (17.9%)	$ 7.59

2. artesunate and mefloquine	200 mg and 250 mg tablets, co-packaged	Switzerland	17 (58.6%)	0	$ 7.05

3. artesunate	50 mg tablets	China	6 (20.7%)	0	$ 4.62

4. artesunate	50 mg tablets	France	24 (82.8%)	7 (25.0%)	$ 5.48

5. artesunate	50 mg tablets	Switzerland	8 (27.6%)	0	$ 5.26

6. artesunate	50 mg tablets	Belgium	28 (96.6%)	3 (10.7%)	$ 3.53

7. artesunate	50 mg tablets	India	17 (58.6%)	0	$ 2.51

8. artesunate	100 mg tablets	Belgium	28 (96.6%)	28 (100%)	$ 4.99

9. artesunate	100 mg tablets	Tanzania	7 (24.1%)	1 (3.6%)	$ 2.19

10. artesunate	100 mg tablets	Tanzania	20 (69.0%)	6 (21.4%)	$ 1.92

11. artesunate	100 mg tablets	Kenya	2 (6.9%)	0	$ 2.31

12. artesunate	200 mg tablets	Switzerland	19 (65.5%)	1 (3.6%)	$ 6.72

13. artemether	40 mg tablets	India	8 (27.6% 0	0	$ 2.24

14. artemether	50 mg tablets	China	24 (82.8%)	15 (53.6%)	$ 4.74

15. artemether	180 mg/60 ml suspension	Belgium	18 (62.1%)	0	$ 4.65

16. artemether	300 mg/100 ml suspension	Belgium	3 (10.3%)	0	$ 5.75

17. dihydroartemisinin	60 mg tablets	Korea	18 (62.1%)	0	$ 4.36

18. dihydroartemisinin	60 mg tablets	China	25 (86.2%)	9 (35.7%)	$ 4.55

19. dihydroartemisinin	160 mg/80 ml suspension	China	20 (69.0%)	0	$ 4.18


Reference strains	International code1	Source

L.(L.)mexicana 	MHOM/BZ/62/BEL21	1

L.(L.)mexicana 	MHOM/BZ/62/M379	1

L.(L.)amazonensis 	IFLA/BR/67/PH8	1

L.(L.)amazonensis 	MHOM/BR/73/M2269	1

L.(L.)garnhami 	MHOM/VE/75/HM76	1

L.(L.)garnhami 	MHOM/VE/76/JAP78	1

L.(L.)pifanoi 	MHOM/VE/57/LL1	1


IHC	FISH

 	Positive	Negative

Positive	9	5

Negative	2	6

P value	0.183


Scenarios (Detailed description in Method section)and total number of respondents	Expected responses (Detailed description in Method section)	Most often selected strategy by French respondents(N = 99)	Agreement in French study with expected choice(Yes/No/Partial)	Most often selected strategy by Swedish respondents[[2]] (N = 59)	Agreement in previous Swedish study with expected choice(Yes/No/Partial)	Agreement between French and previous Swedish study(Yes/No/Partial)

1 N = 96	Quick fix	Quick fix (41%)	Yes	Quick fix (54%)	Yes	Yes

2 N = 97	Quick fix or Symptom- guided MC	Clinical findings-guided MC (53%) (moderate consensus)	No	Symptom-guided MC (44%)	Yes	No

3 N = 91	Try again	2nd opinion (21%) or try again (20%)	Partial	Try again (42%)	Yes	Partial

4 N = 95	Symptom-guided MC or (possibly) Clinical findings-guidedMC	Symptom-guided MC (39%) or Clinical findings- guided MC(39%)	Yes	Symptom-guided MC (46%)	Yes	Yes

5 N = 95	Try again or External help-keep in touch	2nd opinion (27%)	No	Try again (25%) or Clinical findings- guided MC(24%)	Yes	No

6 N = 92	Try again or External help-keep in touch	External help- keep in touch (27%) or try again (26%)	Yes	Try again (37%)	Yes	Yes

7 N = 92	Try again or external help-keep in touch	2nd opinion (48%)	No	Try again (32%)	Yes	No

8 N = 92	2ndopinion	2nd opinion (71%) (excellent consensus)	Yes	2ndopinion (59%)	Yes	Yes

9 N = 91	2ndopinion	2nd opinion (61%) (moderate consensus)	Yes	2ndopinion (59%)	Yes	Yes


Gene name	Description	Adjusted P value (DB/WT)	Adjusted P value (GGQL/DB)

Pgam1	Phosphoglycerate mutase 1	<0.0001	0.0038

Igf1	Insulin-like growth factor 1	0.0060	0.0029

Cpeb4	Cytoplasmic polyadenylation element binding protein 4	0.0141	0.0283

Slc38a2	Solute carrier family 38, member 2	0.0000	<0.0001

Vegfa	Vascular endothelial growth factor A	0.0001	0.0005

Banp	BTG3-associated nuclear protein	<0.0001	0.0100

Rbm38	RNA-binding motif protein 38	0.0078	0.0380

Rasgef1b	RasGEF domain family, member 1B	0.0003	0.0037

Anxa3	Annexin A3	<0.0001	0.0309

Cyp1a1	Cytochrome P450, family 1, subfamily a, polypeptide 1	<0.0001	0.0016

Trib1	Tribbles homolog 1 (Drosophila)	0.0004	0.0118

Nphp3	Nephronophthisis 3 (adolescent)	<0.0001	0.0275

Fhl3	Four and a half LIM domains 3	0.0036	0.0045

Serpine1	Serine (or cysteine) peptidase inhibitor, clade E, member 1	<0.0001	0.0016

Acer2	Alkaline ceramidase 2	<0.0001	0.0016

Arhgap32	Rho GTPase activating protein 32	<0.0001	<0.0001

Atf4	Activating transcription factor 4	0.0044	0.0016

Zc3h6	Zinc finger CCCH type containing 6	<0.0001	0.0136

Tet1	Tet methylcytosine dioxygenase 1	0.0006	0.0016

Klk1b26	Kallikrein 1-related petidase b26	0.0146	0.0189

Ppp1r3c	Protein phosphatase 1, regulatory (inhibitor) subunit 3C	0.0000	0.0029

Ttc30b	Tetratricopeptide repeat domain 30B	<0.0001	0.0054

Fign	Fidgetin	<0.0001	0.0195

AI593442	Expressed sequence AI593442	<0.0001	0.0350

5730480H06Rik	RIKEN cDNA 5730480H06 gene	0.0019	0.0029

Gm26703	Predicted gene, 26703	<0.0001	<0.0001


Risk Factor Increase	Risk Factor	Mean % Change in Daily Visits per Risk Factor Increase	T-test p-value

0.01 ppm	Ozone	3.2 (1.4, 5)	0.000

1 μg m-3	PM2.5	-0.2 (-0.6, 0.2)	0.331

1000 spores m-3	Mold Count	-0.2 (-1.1, 0.7)	0.707

10 grains m-3	Weed Pollen	-2.9 (-6.8, 1.1)	0.148

100 grains m-3	Tree Pollen	1.8 (0.9, 2.6)	0.000

10 grains m-3	Grass Pollen	1.6 (-2, 5.4)	0.378

1°F	Temperature	0.2 (0.1, 0.4)	0.007


Knockout mouse	Phenotype	Reference

TRPC1	No effect on Ang II-induced cardiac hypertrophy	(39)

Reduced pathological cardiac hypertrophy by double knockout with TRPC4

TRPC3	Resistant to pressure-overload-induced cardiac remodeling	(4, 5, 18)

Reduced ischemia–reperfusion (I/R) injury by triple knockout with TRPC6 and TRPC7	(59)

TRPC4	No effect on Ang II-induced cardiac hypertrophy	(39)

Reduced pathological cardiac hypertrophy by double knockout with TRPC4

TRPC5	No further reduction of pathological cardiac hypertrophy to that of double knockout of TRPC1/C4	(39)

TRPC6	Resistant to pressure-overload induced cardiac remodeling	(18)

Reduced I/R injury by triple knockout with TRPC3 and TRPC7	(59)

TRPC7	Reduced I/R injury by triple knockout with TRPC3 and TRPC6	(59)


Category	Variables	Key references

Personal social learning indicators	Willingness to share ideas with other stakeholders	Pelling and High (2005); Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Murray, Roux, and Hill (2010); Muro and Jeffrey (2012); Bos, Brown, and Farrelly (2013); Cundill et al. (2013).

	Development of trust among stakeholders	Pelling and High (2005); Pelling et al. (2008); Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Murray et al. (2010); Muro and Jeffrey (2012); Cundill et al. (2013)

	Participation by all stakeholders	Pelling et al. (2008); Cundill and Fabricius (2009); Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Murray et al. (2010); Muro and Jeffrey (2012)

	Capacity for conflict resolution	Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Muro and Jeffrey (2012)

	Collective action towards project goals	Pelling and High (2005); Pelling et al. (2008); Collins and Ison (2009); Cundill (2010); Roux et al. (2011); Muro and Jeffrey (2012); Bos et al. (2013)

	Continuous interaction and feedback	Cundill and Fabricius (2009); Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Murray et al. (2010)

	Flexibility in planning and implementation	Pelling and High (2005); Pelling et al. (2008); Cundill (2010); Roux et al. (2011); Muro and Jeffrey (2012)

	Willingness to share information	Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Muro and Jeffrey (2012); Bos et al. (2013)

Organisational variables	Empowerment of junior employees to experiment	Pelling and High (2005); Pelling et al. (2008); Nilsson and Swartling (2009); Cundill (2010); Bos et al. (2013)

	Existence of processes to translate feedback into changed practices	Pelling et al. (2008); Cundill (2010); Roux et al. (2011); Murray et al. (2010); Muro and Jeffrey (2012); Bos et al. (2013); Tàbara et al. (2010)

	Sufficient budget to regularly engage with stakeholders	Cundill (2010); Roux et al. (2011); Murray et al. (2010); Cundill et al. (2013)

	Continuous updating of project or planning processes	Nilsson and Swartling (2009); Muro and Jeffrey (2012); Tàbara et al. (2010).

	Support for locally initiated projects	Bos et al. (2013); Cundill et al. (2013)

	Development of local stakeholders’ capacity to engage with projects or interventions	Cundill and Fabricius (2009); Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Muro and Jeffrey (2012)


Tissue	miRNA	Molecular targets	Functions	Reference

Aging heart	miR-21 ↑	ERK–MAP kinase signaling	Profibrotic [role on cardiac fibroblast (CFs)]	(51)

Aging heart	miR-22 ↑	Mimecan/Osteoglycin	Accelerate CF senescence and migration	(52)

Aging heart	miR-18 and miR-19 ↓	Thrombospondin-1 and connective tissue growth factor	Anti-heart failure-related fibrosis during aging	(58)

Aging heart	miR-17-3p ↓	PAR-4	Reduce CF cellular senescence	(61)

Aging heart	miR-34a ↑	Phosphatase 1 nuclear targeting subunit	Increase age-related cardiomyocyte apoptosis and cardiac dysfunction	(62)

Vascular aging	miR-34a ↑	SIRT1	Stimulates senescence in endothelial cell and vascular smooth muscle cells	(68, 71)

Vascular aging	miR-217 ↑	SIRT1	Stimulates endothelial senescence decreasing nitric oxide	(73)

Vascular aging	miR-29 ↑	Collagen and elastin	Extracellular matrix impairment (risk of age-related aortic aneurism)	(74–77)

Vascular aging	miR-146 ↑ or ↓	IRAK and NOX4	Pro-inflammation or anti-oxidative stress	(78, 79)

Vascular aging	miR-92 ↓	Tumor necrosis factor α receptor 1 and collagen type 1	miR-92 reduction mimic arterial aging	(80)


Type of TEAE observed	No. (%) of subjects

ESRD subjects (n = 8)	Healthy subjects (n = 8)	Total (N = 16)

Dosing after hemodialysis	Dosing before hemodialysis

Any TEAE	3 (37.5)	2 (25.0)	1 (12.5)	5 (31.3)

Upper RTI	2 (25.0)	0	0	2 (12.5)

Viral upper RTI	1 (12.5)	0	0	1 (6.3)

Dizziness	1 (12.5)	0	0	1 (6.3)

Headache	0	1 (12.5)	0	1 (6.3)

Infusion site erythema	0	0	1 (12.5)	1 (6.3)

Bronchospasm	0	1 (12.5)	0	1 (6.3)

Papular rash	1 (12.5)	0	0	1 (6.3)


Species (tax id, short name)	Number of proteins	Number of PPI	Source

E. coli K12 (83333, eco)	4121	216426	SNDB [22]

S. typhimurium (99287, stm)	4239	94609	SNDB [22]

C. crescentus (190650, ccr)	3365	40524	SNDB [22]

Yeast (4932, sce)	4738	15417	DIP [13]

Fly (7227, dme)	7165	23484	DIP [13]

Worm (6239, cel)	3029	3393	DIP [13]


Age (yr)*	37.14 ± 7.58

Employment record (yr)*	11.48±4.47

Educational level**	Two trained courses after diploma	8(2.23)

Baccalaureate	311(86.11)

Masters/doctorate	42(11.66)

Marital status **	Married	72(19.91)

Single	279(77.21)

Divorced/Widow	10(2.88)

Gender	Female	339(93.94)

Male	22(6.06)

Current work setting **	General hospital	232(64.35)

Primary health care center	109(30.21)

Private hospital	20(5.54)


Meta-Method	Mean Error

Fisher	0.276

POE with Bss/Wss 	0.375

POE with IC 	0.301

GeneMeta	0.525

RankProd	0.475

Simple	0.617

Cross-Validation	0.329

mDEDS	0.277


Question	Level of ecological framework targeted

Introduction

1. How long have you worked/lived in [name of agency or community]?	N/A

Meaning of Good Health

First, I want you to think about your own health and life.	Intra-Personal

2. What do you consider “good health”?

3. What do you think it means to live a healthy lifestyle?

Now I want you think about [insert name of community]. I’d like for you to think about the community residents that you see every day and interact with either personally or for your job. I also want you to think about the community’s physical environment, stores, restaurants, health and human services, community programs, and so on.	Community/Institutional

4. What does it mean for a community to be “healthy”?

5. Do you consider your community to be healthy?

6. How would you rate the health of this community as a whole on a scale of 1 to 5, with 1 being poor and 5 being excellent?

Probe: What factors did you take into account with your rating?

Enabling and Inhibiting Factors of Good Health

7. What are the values around being healthy in this community?	Inter-Personal

8. What are the unique characteristics (strengths) in [insert name of community] that help residents in being healthy?

Probe: What other characteristics within this community support being healthy?

9. What are the unique characteristics (weaknesses) in [insert name of community] that prevent residents from being healthy?

Probe: What other characteristics within your community discourage residents from being healthy?

10. Which of these characteristics, good and not good, are specific to the [insert Native/MSFW/Latino] culture in this community?

11. What are the biggest (or most important/pressing) health-related concerns in this community?	Community/Institutional

Probe: In your point of view, what are the factors that contribute to these health problems?

12. What resources are available or in place in [insert name of community] to support healthy living among the residents?	Macro Level/Public Policy

Probe: How much are these resources used by community residents?

Probe: How widely known are these resources by community residents?

Wrap Up

13. What are other important health issues in this community that we have not discussed so far?	All


Drug	Cases (n=32)	Controls (n=64)	p

Zidovudine

Yes	11	12	0.15

No	21	52

Lamivudine

Yes	17	28	0.5

No	15	36

Tenofovir

Yes	15	35	0.6

No	17	29

Emtricitabine

Yes	4	20	0.08

No	28	44

Emtricitabine+tenofovir

Yes	4	20	0.08

No	28	44

Zidovudine+lamivudine

Yes	7	11	0.8

No	25	53

Didanosine

Yes	4	4	0.4

No	28	60

Abacavir

Yes	3	4	0.6

No	29	60

Efavirenz

Yes	11	20	0.9

No	21	44

Nevirapine

Yes	3	6	1

No	29	58

Atazanavir

Yes	6	16	0.6

No	26	48

Fosamprenavir

Yes	2	2	0.6

No	30	62

Lopinavir/ritonavir

Yes	2	5	1

No	30	59


Variable	Survivors (n = 36)	Nonsurvivors (n = 25)	P value

cTnT (pg/mL), median (IQL) 	20 (18–24)	34.5 (27.5–41.5)	<0.05*


Materials employed	Composition	Manufacturer

GC Fuji II Universal Restorative	Powder: 95% fluoroaluminosilicate glass (amorphous)5% polyacrylic acid	G.C. Corporation, Tokyo, Japan

Liquid: 50% distilled water40% polyacrylic acid

GC Fuji II Capsule	Powder/liquid ratio (g/g) 0.30/0.11	G.C. Corporation, Tokyo, Japan

GC Fuji II Universal Restorative Liquid	50% distilled water40% polyacrylic acid	G.C. Corporation, Tokyo, Japan

GC Dentin Conditioner	10% polyacrylic acid	G.C. Corporation, Tokyo, Japan


Data set	Number of instances	Number of attributes

Sonar	208	60

Live disorder	345	6

Breast cancer	680	10

Cystic fibrosis	177	Depends on q

Leukemia	355	Depends on q

Lung cancer	91	54675


 	Group O (n = 40)	Group L (n = 39)	p valuesa

Surgical indication	 	 	0.968b

 Inflammation	3 (7.50)	3 (7.69)

 Stricture	24 (60.00)	23 (58.97)

 Internal fistula/mass	11 (27.50)	10 (25.64)

 Hemorrhage	2 (5.00)	3 (7.69)

Type of surgery 	 	 	0.629b

 Small bowel resection	11 (27.50)	10 (25.64)

 Ileocolic resection	21 (52.50)	24 (61.54)

 Colonic resection	8 (20.00)	5 (12.82)

Hand-assisted anastomosis	 	11 (28.21)

Length of incision (cm)	10.30 ± 1.79	5.00 ± 1.23	<0.001

Operation duration (min)	86.85 ± 24.31	121.53 ± 33.62	<0.001

Blood loss (mL)	122.25 ± 53.61	54.10 ± 21.97	<0.001


	No history of MTSS	History of MTSS	P-value	Effect size (r)

Navicular Drop (mm)	7.1 ± 2.0	7.1 ± 1.9	0.98	0.01

Leg Heel Alignment (°)	5.0 ± 1.4	5.1 ± 2.0	0.72	0.08


<underline>Sociodemographics</underline>	<underline>% of full sample</underline>

Age (mean, SD)	32.6, 13.0

Minority/racial group member	50.2

Not married	45.0

No. children in household	49.6

No education beyond high school	37.4

Not employed	45.4

Income below federal poverty line	17.9

<underline>Physical health</underline>

Not pregnant	94.7

Smokes	13.6

Fair/poor health	17.3

<underline>Mental health</underline>

PTSD symptoms	6.3

Anxiety symptoms	21.8

Depression symptoms	13.7

Overwhelmed by stress	12.5

<underline>Mental health help</underline>

Poor mental health	14.2

Perceived need for mental health help	23.2

Utilized mental health help	9.8

<underline>Adult victimization</underline>

Intimate partner violence	9.9

Physically assaulted	19.7

Sexually assaulted	10.6

Death of someone close	29.7

<underline>Childhood victimization</underline>

Lived in foster care	3.4

Lived with someone abusing substances	22.3

Lived with someone mentally ill	16.8

Lived with mother victimized by violence	18.4

Lived with someone incarcerated	7.6

Emotionally abused by adult in home	18. 4

Physically assaulted	19.1

Sexually assaulted	11.2


	GUH (N = 34)	WHC (N = 21)	Total (N = 55)

Age (N = 55)	M = 55.4 SD = 8.2	M = 53.7 SD = 6.7	M = 54.7 SD = 7.6

Race/Ethnicity #

 White (N = 19)	50%	10.5%	35.8%

 African American (N = 30)	38.2%	89.5%	56.6%

 Other (N = 4)	11.8%	0	7.5%

Education

 < HS grad (N = 14)	20.6%	33.3%	25.5%

 Voc/trade or some college (N = 12)	14.7%	33.3%	21.8%

 College Graduate (N = 7)	20.6%	0	12.7%

 Graduate work/degree (N = 22)	44.1%	33.3%	40.0%

Marital Status

 Married (N = 37)	70.6%	61.9%	67.3%

 Other (N = 18)	29.4%	38.1%	32.7%

Internet access at home/work

 Yes (N = 41)	82.4%	61.9%	74.5%

 No (N = 14)	17.6%	38.1%	25.5%

Home/Work Computer Internet Usage (among those with access at home/work)

 Few times yr/few times month (N = 7)	7.1%	38.5%	17.1%

 Once/twice a wk (N = 5)	14.3%	7.7%	12.2%

 Daily (N = 29)	78.6%	53.8%	70.7%

Receiving Health Related Information #

 Prefers Internet (N = 23)	47.1%	36.8%	43.4%

 Prefers Booklet (N = 30)	52.9%	63.2%	56.6%

Willingness to Read Prostate Cancer Info on the Internet #

 Definitely/Probably would (N = 42)	76.5%	84.2%	79.3%

 Definitely/Probably would not (N = 11)	23.5%	15.8%	20.7%

Awareness of Disagreement in Medical Community Regarding Whether to Screen for PrCa

 Unaware of disagreement (N = 45)	82.4%	81.0%	81.8%

 Aware of disagreement (N = 4)	2.9%	14.3%	7.3%

 Not Sure (N = 6)	14.7%	4.8%	10.9%


Drug	n	Median Dosage (mg/kg/day)	Median Length of Treatment (Days)	Side Effects (n)

Rifampicin	415	17.5	240	Itch, vomit and headache (1); rash (1); hypertransaminasemia (4)

Pyrazinamide	411	27	95	Hypertransaminasemia (7); vomit and malaise (1); epigastric pain (1); hyperuricemia (5); drug induced hepatitis (1)

Isoniazid	396	10	242	Drug induced hepatitis (1); hypertransaminasemia (4)

Ethambutol	245	17	86	Vomit and malaise (1); neutropenia (1); drug induced hepatitis (1); epigastric pain (1)

Streptomycin	35	19	31

Moxifloxacin	31	10.3	161	Tendinopathy (1); long QT syndrome (1)

Linezolid	17	19.1	108

Amikacin	12	16.8	24,5

Cycloserine	11	14.1	220

Levofloxacin	7	11.6	202

PAS 1	6	118	172.5

Ethionamide	6	15.4	91.6

Clarithromycin	5	15.6	39.6

Kanamicina	1	10	142

Ciprofloxacin	4	17	238	Vomit and weight loss (1)


Genes groupa	Number of genesb

Glucose-dependent	667 (18%)

Upregulated genes	349

Downregulated genes	318

CcpA-dependent	407 (11%)

Upregulated by CcpA	197

Downregulated by CcpA	210

Regulated by glucose in a CcpA-dependent manner	361 (10%)

Upregulated genes	170

Downregulated genes	191

Regulated by glucose in a CcpA-independent manner	303 (8%)

Upregulated genes	177

Downregulated genes	126

Regulated by CcpA in absence of glucose	43 (1%)

Upregulated by CcpA	8

Downregulated by CcpA	35

Regulated by CcpA independent of glucose	3 (0.08%)

Upregulated by CcpA	2

Downregulated by CcpA	1

Atypical regulation	112 (0.3%)

Upregulated genes	39

Downregulated genes	73


No.	Disease	Medicine	Formulation	Strength	Target size pack

1	Intestinal parasite	Albendazole	tablet	200 mg	2

2	Infectious disease	Amoxicillin	capsule	250 mg	10

	Infectious disease	Amoxicillin	suspension	125 mg	100 ml

3		Aminophyllin	injection	25 mg/ml	1 vial

4	Infectious disease	Amoxicillin_Clavulanic acid	tablet	125 mg + 125 mg, tab	10

	Infectious disease	Amoxicillin_Clavulanic acid	suspension	125 mg + 31.25 mg	100 ml

	Infectious disease	Amoxicillin_Clavulanic acid	suspension	250 mg + 62.50 mg	100 ml

5	Infectious disease	Azithromycin	capsule	250 mg	6

	Infectious disease	Azithromycin	suspension	200 mg/5 ml	100 ml

6	Asthma	Beclomethason	inhaler	50 mg/day	1 inhaler (200 doses)

7	Infectious disease	Benzylpenicillin	injection	600 mg = 1 million IU	1 vial

8	Seizure Disorder	Carbamazepine	tablet	100 mg	20

	Seizure Disorder	Carbamazepine	suspension	100 mg/5 ml	100 ml

9	Infectious disease	Cefazolin	injection	1 g, vial	1 vial

10	Infectious disease	Ceftriaxone	injection	500 mg vial	1 vial

11	Infectious disease	Chloramphenicol	tablet	250 mg	10

	Infectious disease	Chloramphenicol	injection	1 g, vial	1 vial

12	Infectious disease	Chlorpheniramine	tablet	4 mg	24

13	Infectious disease	Clarithromycin	suspension	125 mg/ 5 ml	100 ml

	Infectious disease	Clarithromycin	tablet	125 mg	10

14	Infectious disease	Cotrimoxazole	tablet	100 mg + 20 mg (also expressed as 400 mg + 80 mg)	10

	Infectious disease	Cotrimoxazole	suspension		100 ml

15	Seizure Disorder	Diazepam	tablet	5 mg	10

16	Anemia	Ferrous salt	suspension	30 mg/5 ml	100 ml

17	Fungal infection	Fluconazole	capsule	150 mg	6

18	Infectious disease	Gentamycin	injection	10 mg/ml	1 vial

19	Pain/inflammation	Ibuprofen	tablet	2 mg	24

	Pain/inflammation	Ibuprofen	suspension		100 ml

20	Tuberculosis	Isoniazide	tablet	100 mg	56

21	Pain	Morphine	tablet	10 mg	56

	Pain	Morphine	oral solution	10 mg/5 ml	100 ml

22	Dehydration	ORS	sachet	500 ml	1 sachet

23	Pain/inflammation	Paracetamol	tablet	250 mg	10

	Pain/inflammation	Paracetamol	suppository	125 mg	10

	Pain/inflammation	Paracetamol	suppository	250 mg	10

	Pain/inflammation	Paracetamol	suspension	125 mg	100 ml

24	Seizure Disorder	Phenobarbital	tablet	30 mg	10

	Seizure Disorder	Phenobarbital	injection	100 mg/ml	1 vial

25	Seizure Disorder	Phenytoin	tablet	50 mg,	90

	Seizure Disorder	Phenytoin	suspension	25 mg, 30 mg/5 ml	500 ml

26	Infectious disease	Procain penicillin	injection	1 g, vial	1 vial

27	Asthma	Salbutamol	inhaler	100mcg	1 inhaler (200 doses)

28	Xerophthalmia	Vitamin A	capsule	100.000 IU	50

29	Anemia	Vitamin B6	injection	50 mg/ml	1 vial

30	Dehydration	Zinc	tablet	20 mg	14

31	Spacer	Device


Gene Name	Forward primer sequence (5′-3′)	Reverse primer sequence (5′-3′)

β-actin	ACTGGGACGACATGGAGAAGATC	AAACCTTACCACTCCCGCC

ADRA1B	TCTGGTCGCTGTGCGTGAT	ATCAAGACCACCAAGACATCCG

ARL3	CATCCCTTGCTCTACATTACTTCC	AAACGACGGGTGCCACAG

BAP1	ACCCGCACTCCTCCCTTAT	GAGAACCAAGTGGAGCAGACA

TRPA1	AGTAGCGGCAACATGTCCACC	CCAAACTAACCCTGAAAGACCG


PPAR	Human	Mouse	Zebrafish

PPARA

 Genes	1	1	2

 Splice variants	1	1	1 per gene

 Isoforms	1	1	1 per gene

 Size (cds, bp)	1,407	1,407	pparaa: 1,413pparab: 1,380

 Protein similarity to zebrafish	67% for pparaa 74% for pparab	65% for pparaa 71% for pparab

PPARD

 Genes	1	1	2

 Splice variants	1	1	1 per gene

 Isoforms	1	1	1 per gene

 Size (cds, bp)	1,326	1,323	pparda: 1,491ppardb: 1,554

 Protein similarity to zebrafish	71% for pparda 73% for ppardb	70% for pparda 73% for ppardb

PPARG

 Genes	1	1	1

 Splice variants	4	1	1

 Isoforms	2	2	1

 Size (cds, bp)	PPARG1 = 1,434PPARG2 = 1,518	PPARG1 = 1,428PPARG2 = 1,518	pparg: 1,584

 Protein similarity to zebrafish	67%	67%


	Pre-intervention	Post-intervention

	Intervention(n = 43)	Control(n = 30)	Intervention(n = 37)	Control(n = 28)	P-value

Attitudes (agreement with statement)

Teachers do not need to act as role models for being active	5.0	11.5	0.0	7.5	0.09

It is not the role of the teacher to teach movement skills	14.3	10.0	5.7	19.2	0.10

It is not important that children participate in structured active play	9.8	13.3	0.0	0.0	-

Safety concerns limit active play opportunities in the preschool setting	60.0	70.0	38.9	58.3	0.14

It is not the role of the teacher to teach about healthy eating	14.5	3.5	2.8	15.5	0.07

Parents should be able to send any type of food to school with their child.	7.3	3.3	0.0	3.7	0.25

It is alright to sell chocolates and sweets for fundraising	56.1	56.5	59.0	48.0	0.39

Confidence

I am confident that I can teach movement skills to children.	97.6	90.0	97.3	95.7	0.73

I am confident in talking to parents about their child's movement skills.	80.5	96.7	97.0	90.9	0.33

I am confident in talking to parents about their child's lunchbox contents	76.9	89.7	89.7	95.8	0.40

Confident talking to parents about their child's television viewing	47.5	78.6	68.8	75.0	0.68

Knowledge of recommended guidelines

Daily serves of fruit	100.0	93.0	94.5	96.0	0.79

Daily serves of vegetables	89.7	96.6	94.3	87.5	0.36

Recreational screen time (TV/DVDs) (hrs/day)	84.2	62.1	73.5	87.0	0.22


Probe Set	z-score	DMFS	Gene Symbol	Gene Title

209648_x_at	4.01	-	SOCS5	suppressor of cytokine signaling 5

208127_s_at	3.75	-	SOCS5	suppressor of cytokine signaling 5

209550_at	3.18	-	NDN	necdin homolog (mouse)

201162_at	3.14	-	IGFBP7	insulin-like growth factor binding protein 7

213910_at	2.87	-	IGFBP7	insulin-like growth factor binding protein 7

212279_at	2.91	+	MAC30	hypothetical protein MAC30

213337_s_at	2.88	+	SOCS1	suppressor of cytokine signaling 1


 	Blood culture/IFAT	Total

Positive	Negative

PCR	Positive	25/29	11/7	36/36

Negative	4/3	10/11	14/14

 	Total	29/32	21/18	50/50


	Control group	Study group	Total analysed

Toes	156 (50 %)	156 (50 %)	312

 Males	37	26	63

 Females	44	58	102

Average age	27.19	25.35	26.27

 Standard deviation	9.48	9.04	9.26

 Median (range)	23 (12–50)	23 (10–50)	23 (10–50)


Variable	Description and unit	Mean	Std. Dev.

Hypertension	1if has hypertension; 0 otherwise	0.43	0.49

Obesity	1 if obese; 0 otherwise	0.31	0.46

Age	In years	55.46	16.06

Marital status	1 if married; 0 otherwise	0.56	0.49

Education	1 if some college or higher; 0 otherwise	0.51	0.49

Employment	1 if employed; 0 otherwise	0.40	0. 49

Income	Annual income in dollars	$40,774	$24,815

Gender	1 if male; 0 if female	0.38	0.48

Race	1 if white; 0 if race other than white	0.90	0.29

Sleep	Number of sleepless days in previous month	8.50	10.56

Drinks	1 if drinks alcohol; 0 otherwise	0.34	0.47

Smokes	1 if smokes; 0 otherwise	0.21	0.41

Exercise	Number of minutes engaged in exercise for the previous week	403.57	674.95


References	Primary outcomes	Secondary outcomes

Fiske (strong)1[17]	There was no difference in sales of healthier food options between intervention and control groups.

Kocken (strong) [20]	Higher sales of healthier food options were observed in intervention groups compared to control groups.


Section of economizer	Condition design

	Length was 250 mm

Evaporator section	Hot water flow was 80°C

	Volumetric flow rate was 5 l/min

Adiabatic section	Length was 250 mm

	Length was 250 mm

Condenser section	Cool water flow was 25°C

	Volumetric flow rate was 1 l/min


Item	Dimension	Missing values (%)

1. I work hard to keep my HIV a secreta	Disclosure concerns	0.0

2. Most people believe a person who has HIV is dirtya	Public attitudes	3.4

3. Having HIV makes me feel uncleana	Negative self-image	8.6

4. Most people think a person with HIV is disgustinga	Public attitudes	1.7

5. Having HIV makes me feel I'm a bad persona	Negative self-image	0.0

6. Most with HIV are rejected when others learna	Public attitudes	5.2

7. I am very careful whom I tell that I have HIVa	Disclosure concerns	3.4

8. Having HIV in my body feels disgustinga	Negative self-image	0.0

9. I have been hurt by how people reacted to learning I have HIV	Personalized stigma	19.0

10. I worry that people who know I have HIV will tell others	Disclosure concerns	13.8

11. I have stopped socializing with some due to their reactions to my HIV	Personalized stigma	19.0

12. I have lost friends by telling them I have HIV	Personalized stigma	24.1


Variable	<35	p-value	≥35	p-value

 	Adjusted odds ratio (95% CI)	 	Adjusted odds ratio (95% CI)

a. Adjusted Confounder Model for not having tested for HIV in the past 2 years, stratified by age

Asian ethnicity	2.04 (1.08-3.86)	0.028	0.65 (0.28-1.51)	0.32

English or French as first language	1.29 (0.69-2.43)	0.426	1.28 (0.62-2.66)	0.51

Age (in years) of participate at study enrolment.	0.97 (0.92-1.02)	0.245	1.01 (0.98-1.03)	0.58

IDU ever	0.81 (0.41-1.56)	0.522	0.42 (0.20-0.86)	0.017

At the present time, do you smoke cigarettes?	1.31 (0.84-2.03)	0.234	1.15 (0.68-1.95)	0.60

Not told doctor of male sex partners	5.83 (3.67-9.24)	<0.001	3.47 (1.90-6.35)	<0.001

b. Adjusted Confounder Model for not having tested for Hepatitis C Virus in the past 2 years, stratified by age

Asian ethnicity	2.30 (1.27-4.19)	0.006	1.05 (0.51-2.15)	0.90

English or French as first language	1.25 (0.71-2.22)	0.435	1.14 (0.61-2.13)	0.68

Age (in years) of participate at study enrolment.	0.99 (0.95-1.04)	0.664	1.02 (1.00-1.04)	0.063

Not told doctor of male sex partners	7.06 (4.30-11.60)	<0.001	2.43 (1.41-4.18)	0.001

c. Adjusted Confounder Model for not having tested for syphilis in the past 2 years, stratified by age

Asian ethnicity	0.85 (0.45-1.61)	0.625	0.67 (0.32-1.40)	0.29

English or French as first language	1.19 (0.66-2.15)	0.563	0.81 (0.43-1.52)	0.51

Age (in years) of participate at study enrolment.	0.96 (0.92-1.01)	0.124	0.99 (0.97-1.01)	0.48

IDU ever	1.59 (0.86-2.93)	0.137	1.77 (1.08-2.90)	0.023

At the present time, do you smoke cigarettes?	0.66 (0.44-1.00)	0.048	0.65 (0.43-0.98)	0.038

Not told doctor of male sex partners	0.11 (0.07-0.18)	<0.001	0.24 (0.14-0.42)	<0.001


Variable	Training groups	P value‡

	Control groupn = 60Mean (SD)	Endurance n = 59Mean (SD)	Strength n = 60Mean (SD)

Demographic

 Age, years	46 (5)	46 (6)	45 (6)	0.73

 Height, cm	164 (5)	165 (6)	165 (5)	0.74

 Weight, kg	69 (12)	68 (10)	67 (11)	0.64

 Body mass index	26 (4)	25 (3)	25 (3)	0.40

Clinical characteristic

 Duration of neck pain, years	8 (5)	9 (6)	8 (6)	0.30

 Neck pain, mm (VAS†, scale 0-100)	58 (20)	56 (22)	57 (20)	0.89


	mean (SD)

Age, y	31.6 (4.3)

Age at menarche, y	13.2 (1.5)

Pre-pregnancy BMI, kg/m2	24.3 (3.7)

	% (n)

Pre-pregnancy BMI group

 Underweight (BMI < 18.5)	11 (8)

 Normal weight (BMI 18.5 - 24.9)	52 (61)

 Overweight (BMI 25 - 29.9)	30 (36)

 Obese (BMI ≥ 30)	7 (8)

Educational level

 Not completed post high school education	32 (38)

 Completed post high school education	68 (80)


		Status at consent

		High non-tryer	High tryer	Pregnant

		%	%	%

Age, years	<18	0	0	1.4

	18–19	*	0	3.3

	20–34	90.9	83.7	76.5

	35+	*	16.3	18.7

	Mean (standard deviation)	27.7 (4.0)	30.7 (4.1)	29.2 (5.7)

Race/ethnicity	Asian, non-Hispanic	*	*	4.2

	Black, non-Hispanic	*	*	6.4

	Hispanic	22.7	10.2	20.0

	Other^	20.5	20.4	8.0

	White, non-Hispanic	50.0	67.3	61.5


Organism	Degradosome-dependence	PNPase role	References

Yersinia pestis	?	Catalytic activity plays an essential role in cold growth	Rosenzweig et al., 2005

	?	Required for virulence in a catalytic-activity-independent manner	Rosenzweig et al., 2005

	?	S1 domain sufficient for mediating virulence	Rosenzweig et al., 2005

	?	The first 15 aa residues of the S1 domain are dispensable for virulence; however, the first 30 aa residues are required for virulence	Rosenzweig et al., 2007

	?	Amino acid residue F638 within the PNPase S1 domain is required for virulence and cold growth	Rosenzweig et al., 2007

Yersinia pseudotuberculosis	No	S1 and KH domains also contribute to cold growth.	Rosenzweig et al., 2005

	No	Degradosome-independent role in cold growth	Henry et al., 2012

	Yes	Degradosome assembly required for virulence	Yang et al., 2008

	Yes	Degradosome-dependent role in oxidative stress response	Henry et al., 2012

	No	PNPase is dispensable for antibiotic/chemical stress responses	Henry et al., 2012


Number	Outcomes

1	Patient-provider communication

2	Monitor treatment response

3	Detect unrecognised problems

4	Changes to patient health behaviour

5	Changes to patient management

6	Improved patient satisfaction

7	Improved health outcomes

8	Strong & effective quality improvement

9	Increased transparency, accountability, public reporting

10	Better system performance (monitoring, planning, financing; evaluating, responding)

11	Mediating variables on the effect (both at individual and organisation level)

12	Possible subgroup effects


Stratification criteria	Description

Physician Integrated Network (PIN) [30]	A Manitoba Health primary care renewal initiative that focuses on fee-for-service (FFS) physician groups.

Its goal is to facilitate systemic improvements in the delivery of primary care.

Objectives:

● To improve access to primary care

● To improve Primary Care Providers’ access to and use of information

● To improve the work life for all primary care providers

 	● To demonstrate high quality primary care with a specific focus on Chronic Disease Management

Uniting Primary Care and Oncology Network (UPCON)[31]	A collaborative partnership between Winnipeg family practice clinics/primary health care centres and CancerCare Manitoba (CCMB) that is dedicated to promoting and supporting the shared care of the cancer patient.


Tissue sample	Type of core	No. of cores in TMA blocks

Control Normal Samples	Normal	119

DCIS	Normal in DCIS	12

DCIS pure lesion	54

IDC	Normal in IDC	61

DCIS in IDC	39

IDC pure lesion	120


 	Dry mucus membranes (eyes/mouth)	Lighter/uneasy sleep	Heavier sleep	Sleepiness at daytime	Increased fatigue	Dizziness

Patient #1	x	x	 	 	x

Patient #2	x	 	 	x

Patient #3	x	x

Patient #4	x	 	 	 	 	x

Patient #5	x	 	x


	Surgery group	Packing group	P

Re-bleeding	0	4	0.001

Discomfort after the treatment	2.4±1.4	7.6±1.0	0.001

Adhesion of nasal cavity	2	7	0.007


Gene	Primer sequences

hsa-miR-155	RT	5′-GCGCGTGAGCAGGCTGGAGAAATTAACCACGCGCACCCCT-3′

Forward	5′- CTTAATGCTAATCGTGAT -3′

Reverse	5′- GAG CAG GCT GGA GAA -3′

hsa-miR-146a	RT	5′-GCGCGTGAGCAGGCTGGAGAAATTAACCACGCGCAACCCA -3′

Forward	5′- CTGAGAACTGAATTCCA -3′

Reverse	5′- GAG CAG GCT GGA GAA -3′

U6	RT	5′-CGCTTCACGAATTTGCGTGTCAT -3′

Forward	5′- CTCGCTTCGGCAGCACATA -3′

Reverse	5′- CGCTTCACGAATTTGCGTG -3′

TGF-β1	Forward	5′- CCAACTATTGCTTCAGCTCCA -3′

Reverse	5′- GTGTCCAGGCTCCAAATGT -3′

TNF-α	Forward	5′- CCCAGGGACCTCTCTCTAATCA -3′

Reverse	5′- AGCTGCCCCTCAGCTTGAG -3′

GAPDH	Forward	5′-CCCCTTCATTGACCTCAACTAC-3′

 	Reverse	5′-GATGACAAGCTTCCCGTTCTC-3′


Gene_symbol	Description	Log2 Ratio (A253-5/A253-0)	P value

MAPK10	mitogen-activated protein kinase 10	−1.1440	0.000264947

AKT1	v-akt murine thymoma viral oncogene homolog 1	1.1076	0.014492851

PDGFB	platelet-derived growth factor beta polypeptide	1.0834	6.23066E-05

BIRC3	baculoviral IAP repeat containing 3	1.0176	0.001517394

PGF	placental growth factor	−1.0496	0.025969431

COL4A1	collagen, type IV, alpha 1	2.1236	1.58011E-20

FN1	fibronectin 1	3.6490	3.35978E-24

THBS1	thrombospondin 1	1.0290	0.000135356

FLT1	fms-related tyrosine kinase 1	1.2325	0.025381832

RASGRF1	Ras protein-specific guanine nucleotide-releasing factor 1	1.7221	1.11117E-05

CCND2	cyclin D2	2.3619	8.02038E-19

COL5A2	collagen, type V, alpha 2	1.2806	0.030736616

TNC	tenascin C	1.6496	9.83873E-07

PARVA	parvin, alpha	1.2195	9.20291E-07


Item	Mean	SD	Range	95% CI

1. I have a desire to succeed	4.6	0.62	1–5	4.56; 4.72

2. I have my own plan for how to stay or become well	3.9	0.92	1–5	3.80; 4.05

3. I have goals in life that I want to reach	4.2	0.90	1–5	4.08; 4.32

4. I believe that I can meet my current personal goals	3.7	0.98	1–5	3.59; 3.85

5. I have a purpose in life	3.8	0.94	1–5	3.72; 3.97

6. Even when I don’t care about myself, other people do	4.1	0.83	1–5	4.0; 4.21

7. Fear doesn’t stop me from living the way I want to	3.1	1.30	1–5	2.90; 3.25

8. I can handle what happens in my life	3.3	1.02	1–5	3.20; 3.47

9. I like myself	3.2	1.20	1–5	2.99; 3.31

10. If people really knew me, they would like me	3.7	0.84	1–5	3.60; 3.82

11. I have an idea of who I want to become	3.5	1.05	1–5	3.40; 3.67

12. Something good will eventually happen	4.0	0.81	1–5	3.93; 4.14

13. I’m hopeful about my future	3.9	0.99	1–5	3.72; 3.97

14. I continue to have new interests	3.7	1.09	1–5	3.57; 3.86

15. Coping with my mental illness is no longer the main focus of my life	3.1	1.23	1–5	2.98; 3.30

16. My symptoms interfere less and less with my life	3.4	1.20	1–5	3,25; 3.54

17. My symptoms seem to be a problem for shorter periods of time each time they occur	3.5	1.13	1–5	3.32; 3.61

18. I know when to ask for help	3.9	1.06	1–5	3.78; 4.05

19. I am willing to ask for help	4.1	0.92	1–5	4.01; 4.25

20. I ask for help when I need it	3.8	1.08	1–5	3.68; 3.96

21. I can handle stress	3.0	1.14	1–5	2.88; 3.18

22. I have people I can count on	4.3	0.78	1–5	4.18; 4.38

23. Even when I don’t believe in myself, other people do	4.0	0.87	1–5	3.88; 4.10

24. It is important to have a variety of friends	3.5	1.40	1–5	3.31; 3.67

Summary scales

Personal confidence and hope (mean of items 7, 8, 9, 10, 11, 12, 13, 14 & 21)	3.5	0.68	1.67–5	3.40; 3.58

Willingness to ask for help (mean of items 18, 19 & 20)	4.0	0.89	1–5	3.84; 4.07

Goal and success orientation (mean of items 1, 2, 3, 4 & 5)	4.1	0.63	1.4–5	3.99; 4.15

Reliance on others (mean of items 6, 22, 23 & 24)	4.0	0.68	2–5	3.88; 4.06

Not dominated by symptoms (mean of items 15, 16 & 17)	3.3	0.95	1–5	3.21; 3.45

Total scale (mean of items)	3.7	0.56	1.92–5	3.66; 3.80

Total scale (sum of items)	89.5	13.39	46–120	87.75; 91.24


Study design	Methods & numbers	Research instruments	Respondents

Qualitative study	*GDs: 14 (One group from each hospital)	GD guideline: semi-structured open-ended questions with probes	From district hospitals: civil surgeon, obstetrics and pediatrics consultants, anesthesiologist, nursing superintendent, and two senior staff nurses

From MCWCs: deputy director of family planning, anesthesiologist, medical officer, one nurse, and one family welfare visitor

From UHCs: upazila health and family planning officer, obstetrics and gynecology specialists, pediatrician, anesthesiologist, resident medical officer, and one nurse

**IDIs:56 (four interviews from each hospital)	IDI guideline: semi-structured open-ended questions with probes	From district hospitals, MCWCs, and UHCs: One laboratory technician/pharmacist, one ward master/nursing supervisor, one ancillary staff from the maternal or neonatal wards, and one cleaner

Quantitative study	Exit interviews: 112 (eight exit interviews from each hospital)	Structured questionnaire	Patients or their attendants from maternal, labor, and neonatal wards at district hospitals, MCWCs, and UHCs


Colorectal cancer characteristic	Black Mississippians	White Mississippians	Difference (Black–White)	P value

Statistically-significant health disparities

 % (Age 50+) reporting NEVER had a sigmoidoscopy or colonoscopy (average: 2006, 2008 and 2010 BRFSS)	53.2 %	41.9 %	11.3 %	<.0001

 Age-adjusted colorectal cancer incidence rate (per 100,000; 2006–2010 MCR data)	64.9	50.5	14.4	<.0001

 Age-adjusted colorectal cancer mortality rate (per 100,000; 2006–2010 MCR data)	26.2	17.5	8.8	0.0001

 CRC mortality-to-incidence rate	0.40	0.35	0.05	0.0035

No discernible differences between groups

 % Advanced stage (regional + distant disease) at initial diagnosis	52.9 %	52.3 %	0.6 %	0.7926


Database	Crops	Web link	Reference

Gramene	Grasses	http://www.gramene.org	Tello-Ruiz et al., 2016

International Rice Informatics Consortium	Rice (Oryza sativa)	http://iric.irri.org	n/a

Maize Genetics and Genomics Database	Maize (Zea mays)	http://www.maizegdb.org	Lawrence et al., 2004

SoyKB	Soybean (Glycine max)	http://soykb.org	Joshi et al., 2014

T3 Triticaceae toolbox	Wheat (Triticum aestivum), barley (Hordeum vulgare) and oat (Avena sativa)	https://triticeaetoolbox.org/	Blake et al., 2016

Wheat Information System	Wheat (Triticum aestivum)	http://wheatis.org	n/a


Family	Name	Local RDB	National RL rank	Main habitat	Life forms

Azollaceae	Azolla japonica	35	VU	Paddy, Ditch	perennial fern

Hydrocharitaceae	Blyxa echinosperma	42	VU	Paddy, Ditch	annual

Alismataceae	Caldesia parnassifolia	37	VU	Pond, Lake, Paddy	perennial

Compositae	Gnaphalium hypoleucum	40	VU	Forest edge	annual

Isoetaceae	Isoetes japonica	36	NT	Pond, Paddy, Ditch	perennial fern

Compositae	Ixeris chinensis subsp. strigosa	40	VU	Grassland, Roadside	perennial

Labiatae	Leonurus macranthus	39	VU	Grassland	perennial

Marsileaceae	Marsilea quadrifolia	46	VU	Paddy, Ditch	perennial fern

Pontederiaceae	Monochoria korsakowii	39	NT	Lake, River, Ditch, Paddy(fallow)	annual

Labiatae	Mosla japonica	36	NT	Roadside	annual

Najadaceae	Najas gracillima	40	NT	Pond, Paddy	annual

Menyanthaceae	Nymphoides peltata	40	NT	Lake, Pond, Paddy	perennial

Saxifragaceae	Penthorum chinense	41	NT	Swamp	perennial

Polygonaceae	Persicaria foliosa var. paludicola	36	VU	Swamp, Paddy(fallow), Pond	annual

Polygonaceae	Persicaria taquetii	36	VU	Swamp, Paddy	annual

Potamogetonaceae	Potamogeton berchtoldii	44	NT	Lake, Pond, River, Ditch	perennial

Salviniaceae	Salvinia natans	40	NT	Paddy, Ditch	annual fern

Compositae	Saussurea pulchella	39	VU	Grassland, Forest edge	annual

Sparganiaceae	Sparganium fallax	41	NT	Lake, Pond, River	perennial

Sparganiaceae	Sparganium stenophyllum	41	VU	Lake, Pond	perennial

Trapaceae	Trapa incisa	37	VU	Lake, Pond, Ditch, Paddy	annual

Lentibulariaceae	Utricularia uliginosa	43	NT	Swamp	perennial

Asclepiadaceae	Vincetoxicum pycnostelma	44	NT	Grassland	perennial


Rat number	Control group	Cyanoacrylate group

Researcher 1	Researcher 2	Researcher 1	Researcher 2

1	0	0	1	1

2	0	0	0	0

3	2	2	1	2

4	2	2	2	2

5	1	1	2	2

6	2	2	1	1

7	0	0	1	2

8	2	2	2	1


SSP no.	Accession no.	Protein Description	Mass in kDa (experiment/predicted)	pI (experiment/predicted)	Sequence coverage (%)	Number of peptides matched	Mowse score	Error (ppm)

pH 4–7

2120	6065880	Heterogeneous nuclear ribonucleoprotein H2	38.43/49.52	3.96/5.89	46	15	171	14

3609	515634	Ubiquinol-cytochrome-c reductase complex core protein I, mitochondrial precursor	54.55/52.75	5.30/5.94	46	15	170	17

3617	4826760	Heterogeneous nuclear ribonucleoprotein F	57.18/45.87	5.25/5.38	31	8	88	9

4422	57093855	Similar to heterogeneous nuclear ribonucleoprotein H (hnRNP H)	38.53/46.38	4.46/6.61	43	12	131	6

pH 6–11

7818	8574295	Voltage-dependent anion channel 2	20.00/31.65	9.43/7.49	41	8	88	18

7821	21619296	Guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1	20.00/34.95	9.40/8.37	23	7	72	9


	Control (n = 20)	Imagery (n = 20)

	mean ± SD	mean ± SD

Did you ....

... feel your imagery improved? (1: not at all, 7: considerably)	5.45 ± 1.10	5.80 ± 0.77

... image as instructed and practiced? **(1: not at all, 7: exactly)	5.65 ± 0.67	6.20 ± 0.70

... notice any movement in the non-dominant hand? (1:not at all, 7: full grasping)	3.70 ± 1.08	3.32 ± 1.25

How ...

... easy to image the feelings? (1: very hard, 7: very easy)	5.00 ± 1.41	5.20 ± 1.01

... clear and vivid was the imagery? (1: no image at all, 7: perfectly clear/vivid)	5.40 ± 0.94	5.45 ± 0.76


Parameter	Activity rate	Time (%) in novel	Crossing/min

VEH controls	3.79 ± 0.21	79.7 ± 1.09	2.55 ± 0.26

DAT-i mice	4.10 ± 0.22	78.6 ± 1.75	2.98 ± 0.33


Primers	Sequence (5′-3′)

Primers for gene disruption and complementation

 LwblA-F	AAGCTTTCGGGTACGCCATCTCGTA

 LwblA-R	TCTAGAGCTGCTCCCTGAACGAACA

 RwblA-F	GGATCCACGACGAGGTGTACGAGAAC

 RwblA-R	GATATCTGACGCTGCTGGAGGAGAT

 Kan-F	TCTAGAGATCCCCTGGATACCGCTCG

 Kan-R	GGATCCGTACCCGAACCCCAGAGTC

 wblAJ-F	AACTGGCGGCGGTGAATA

 wblAJ-R	ACGGACGGAGCACATATAGG

 CwblA-F	GGATCCGCCTGAACGGACGGAGCACATA

 CwblA-R	TCTAGAAGCACACTGACACCGAGGAACTTGGC

Primers for qRT-PCR

 RTsanG-F	GGCGTACACAGCTCAAGAGC

 RTsanG-R	AATTCGTCGATGAGCTGATC

 RTsanN-F	AGATCATGCGCTCGGACTGT

 RTsanN-R	TGGCGTGCAGGATCGGTA

 RTsanO-F	ACTGCGATCCGTGGTCAA

 RTsanO-R	TGTACTCCAGGCACTCCC

 RTsanF-F	CGGCGCTGGAGGAACGTAC

 RTsanF-R	GGGTGTAGAGGCCGATGCT

 RThrdB-F	GCTGGCCAAGGAACTCGACAT

 RThrdB-R	CGAAGCGCATGGAGACGACG


Gene Locus ID	Gene description	Normalized Fold (Log2)

P	HC	PHC

GSVIVT00016386001	Vitis vinifera respiratory burst oxidase homolog protein E (VvRBOHE)	0.30 ± 0.21	1.11 ± 0.18	−1.22 ± 0.06

GSVIVT00002525001	Vitis vinifera respiratory burst oxidase homolog protein A (VvRBOHA)	−0.64 ± 0.06	−1.53 ± 0.29	−1.96 ± 0.16

GSVIVT00031598001	Vitis vinifera peroxidase 72 (VvPOD72)	1.59 ± 0.77	2.09 ± 1.18	4.19 ± 0.18

GSVIVT00031723001	Vitis vinifera peroxidase 12 (VvPOD12)	−0.79 ± 0.05	−0.74 ± 0.25	−1.71 ± 0.13

GSVIVT00020782001	Vitis vinifera alpha-dioxygenase 1 (VvDOX1)	1.83 ± 1.16	2.82 ± 0.55	0.13 ± 0.25

GSVIVT00001920001	Vitis vinifera glutathione peroxidase 2 (VvGPX2)	0.34 ± 0.39	0.28 ± 0.45	1.10 ± 0.54

GSVIVT00004080001	Vitis vinifera catalase isozyme 1-like (VvCAT1)	−0.35 ± 0.17	−1.52 ± 0.02	−1.57 ± 0.15

GSVIVT00036747001	Vitis vinifera cytosolic ascorbate peroxidase (VvAPX3)	−0.47 ± 0.24	−1.05 ± 0.09	−1.75 ± 0.04

GSVIVT00007083001	Vitis vinifera superoxide dismutase [Fe] 3, chloroplastic (VvFSD3)	0.40 ± 0.17	0.17 ± 0.10	1.82 ± 0.11

GSVIVT00014163001	Vitis vinifera superoxide dismutase [Fe], chloroplastic (VvFSD)	0.50 ± 0.13	0.33 ± 0.22	−1.60 ± 0.17

GSVIVT00003173001	Vitis vinifera alternative oxidase 2, mitochondrial (VvAOX2)	0.44 ± 0.16	2.43 ± 0.37	1.07 ± 0.18

GSVIVT00036443001	Vitis vinifera hemoglobin-2 (VvHB2)	−0.52 ± 0.43	4.41 ± 0.34	3.08 ± 0.43


Background characteristics	Infants starting the intervention (N = 86)	Infants completing 3 weeks (N = 81)

	Acupuncture group (n = 46)	Control group (n = 40)	Acupuncture group (n = 43)	Control group (n = 38)

Firstborn, n (%)	22 (48)	22 (55)	21 (48)	21 (55)

Gender, female, n (%)	22 (48)	19 (48)	21 (50)	19 (50)

Gestational age, weeks. Mean (SD)	39.2 (1.5)	39.5 (1.3)	39.3 (1.4)	39.5 (1.3)

Age when colic started, weeks. Mean (SD)	1.9 (1.3)	1.5 (1.0)	2 (1.3)	1.5 (1)

Age at inclusion, weeks. Mean (SD)	5.0 (1.9)	5.3 (1.7)	5.1 (1.9)	5.2 (1.6)

Solely breastfed, n (%)	35 (76)	26 (65)	32 (74)	25 (66)

Having a parent and/or sibling with food intolerance/allergy, n (%)	17 (37)	18 (45)	15 (35)	17 (45)

Having a parent and/or sibling who had had infantile colic, n (%)	29 (63)	23 (58)	25 (58)	20 (53)

Have tried simeticone, n (%)	43 (93)	37 (92)	40 (93)	35 (92)

With no effect, n (%)	28 (61)	25 (63)	26 (60)	23 (61)

With uncertain effect, n (%)	15 (33)	12 (30)	14 (33)	12 (32)

Have tried lactobacillus reuteri, Semper Magdroppar ®, n (%)	6 (13)	7 (18)	6 (14)	6 (16)

With no effect, n (%)	4 (9)	7 (18)	4 (9)	6 (16)

With uncertain effect, n (%)	2 (4)	0 (0)	2 (5)	0 (0)

Have tried a diet free from cow'rotein without effect, n (%)	33 (72)	32 (80)	31 (72)	30 (79)

Changed to this diet during the intervention weeks, n (%)	1 (2)	1 (3)	1 (2)	1 (3)

Not ensured if this diet is tried, n (%)	12 (26)	7 (18)	11 (26)	7 (18)

Received antibiotics, either through mother's medication or by own intake, n (%)	14 (30)	10 (25)	12 (28)	9 (24)


	1995	2001	Change %

Admitted patients/doctor/year	101	87	-13.9

Admitted patients/nurse/year	24	22	-8.3

Admitted patients/office staff/year	106	83	-21.7

In-hospital patients at all hours	813	793	-2.5

In-hospital patients at all hours/doctor	2,2	1,6	-28.3

In-hospital patients at all hours/nurse	0.5	0,39	-20.0

In-hospital patients at all hours/office staff	2,3	1.5	-34.8

Deliveries/midwife/year	57	44	-22.8

Out-patients consultations/doctor/year	629	530	-15.7

Out-patients consultations/nurse/year	147	134	-8.8

Out-patients consultations/office staff/year	656	503	-23.3

Surgical procedures/doctor/year – total*	160	128	-20.0

 General surgery	151	134	-11.4

 Orthopedic surgery	189	155	-18.0

 Neurosurgery	98	100	+2.0

 Otorhinolaryngology	177	125	-29.4

 Ophthalmology	135	152	+12.6

 Gynecology	109	71	-34.9

Anesthetized patients/anesthesiologist/year§	661	534	-19.2

Hours with anesthesia/anesthesiologist/year	1 322	1 148	-13.2

Imaging procedures/radiologist/year	7 003	5 198	-25.8

Imaging procedures/radiology technician/year	2 436	2 077	-14.7

Lab test and procedures/technologist/year#	15 981	15 256	-4.5


Outcome	P value

Arthralgia	0.390

Bone pain	0.608

Back pain	0.744

Pain in extremity	0.056

Myalgia	0.794

LS BMD 12 months (normal at baseline-ZOL trials)	0.0003

LS BMD 12 months (osteopenic at baseline-ZOL trials)	0.296

LS BMD 12 months (residronate and ibandronate trials)	0.345


Factor	Cronbach's alpha	Number of items

Privacy	.756	3

Culture	.926	3

Attitude toward telemedicine 	.755	3

Benefit	.729	5

Connectivity 	.794	3

IT capability	.706	3

Compatibility 	.763	3

Data warehouse	.749	3

Technical support	.787	3

Top management support	.706	3

Cost	.728	4

Policy	.815	3

Upper-level leadership	.818	3


 	Patients (n = 38)	Controls (n = 23)

Median age (range) years	37 (18 to 50)	36 (24 to 49)

Sex distribution	26 F/12 M	15 F/7 M

CIS/MS at 12 months	19/19	—

Median lesion volume (range) mL	0.54 (0 to 38.1)	—

Median number of new lesions 	1 (0 to 4)	—

Median OR lesion volume (range) mL	0.06 (0 to 21.3)	—


Construct	Measure	Administration

Primary Outcome measure

Symptom Severity	Irritable Bowel Symptom Severity Scale	Pre, 2 wk, 3 mo, 6 mo, 12 mo post

Secondary Outcome measures

Symptom frequency	Daily Symptom Diary	Daily during the intervention and for 2 weeks post

IBS-related anxiety	Visceral Sensitivity Index	Pre, 2 wk, 3 mo, 6 mo, 12 mo post

Economic impact of IBS	The Work Productivity and Activity Impairment for IBS (WPAI: IBS)	Pre, 2 wk, 3 mo, 6 mo, 12 mo post

Co-Morbid Symptoms	Recent Physical Symptoms Questionnaire (RPSQ)	Pre, 2 wk, 3 mo, 6 mo, 12 mo post

General psychological distress	Brief Symptom Inventory (BSI)	Pre, 2 wk, 3 mo, 6 mo, 12 mo post

Anger and its expression	The State-trait Anger Expression Inventory (STAXI)	Pre, 2 wk, 3 mo, 6 mo, 12 mo post

Maladaptive coping methods	Coping Strategies Questionnaire (CSQ)	Pre, 2 wk, 3 mo, 6 mo, 12 mo post

Quality of life specific to IBS	IBS-QOL	Pre, 2 wk, 3 mo, 6 mo, 12 mo post

Effect modification measures

Expectancy of success of intervention	Borkovec and Nau credibility scales	Prior to second session

Catalogue of distressing prior events	Family Inventory of Life Events (FILE)	Pre intervention only

Demographics	Age, race, education, marital status, income	Pre intervention only

Process measures

Measure of mindfulness: Multiple constructs	Five Facet Mindfulness Questionnaire (FFMQ)	Pre, 2 wk, 6 mo, 12 mo post

Measure of mindfulness: Acceptance construct	Toronto Mindfulness Scale	Pre, 2 wk, 6 mo, 12 mo post


Organizations	Carbohydrates	Fiber	Protein	Fat

American Diabetes Association (ADA)	50–60%	Not specified	10–15%	30–35%

The British Diabetic Association/Diabetes UK	45–60%	<30 g/day	30–35%	<35%

European Association for the Study of Diabetes (EASD)	45–60%	Increase fiber with low-GI food	10–20%	35%

The Canadian Diabetes Association (CDA)	50–60%	25–35 g/day	11%	30%

Japan	60%	1 fruit + 400 g vegetables	15–20%	20–25%

South Africa	50–60%	40 g/day	12–30%	≤30%

India	>65%	40 g/day	12–20%	<21%

Mediterranean diet	40–42%	~23 g/day	~16%	40–42%


Gene	Reagent Sequences

MIP-1α	F; AGCTGACACCCCGACTGC

	R; GTCAACGATGAATTGGCGTG

	P; TGCTGCTTCTCCTACAGCCGGAAGAT

MIP-1β	F; AGCTCTGCGTGTCTGCCC T

	R; GCTGAGAACCCTAGAGCACA

	P; TCTCCT CTTGCTCGTGGCTGCCTT

TNFα	F; TCCAGGCGGTGCCTATGT

	R; GAGCGTGGTGGCCCC

	P; TCAGCCTCTTCTCATTCCTGCTTGTGG

iNOS	F; TGATGTCCGAAGCAAACATCA

	R; TGTGGCTCCCATGTTGCAT

	P; TTCAGATCCCGAAACGCTTCACTTCC

IL-1β	F; TTGGGCCTCAAAGGAAAGAAT

	R; TCTCCAGCTGCAGGGTGG

	P; TATACCTGTCCTGTGTAATGAAAGACGGCA CA

IκBα	F; CGGAGGACGGAGGACTCGTT

	R; ACTTCCATGGTCAGCGGCT

	P; TGCACTTGGCAATCATCCACGAAGA

FasL	F; TACCACCGCCATCACAACC

	R; TTTGTGTTGTGGTCCTTCTTCTTTAG

	P; CTCCCACTGCCGCCACTGACC

GFAP	F; GGAGCTCAATGACCGCTTTG

	R; AGCGCCTTGTTTTGCTGCTC

	P; CAGCTACATCGAGAAGGTTCG

RANTES	F; TCTTGCAGTCGTGTTTGTCAC

	R; TCTTGAACCCACTTCTTCTCT

	P; AGGAACCGCCAAGTGTGTGC

CCR5	F; GGAATGACACACTGCTGCCTAA

	R; GAACACTGAGAGATAACTCCGGAAC

	P; CCCTGTCATCTATGCCTTTGTTGGAGAGA


Sexual behaviors	Number (%)

Diagnosed with an STI in the past 6 months	16 (10.8)

Sought treatment for most recent STI symptom (n = 16)	2 (11.1)

Facility where the most recent STI was treated

 Public health center/hospital (n = 2)	1 (50.0)

 Non-governmental clinic/hospital (n = 2)	1 (50.0)

Had sexual intercourse in the past 3 months	59 (41.3)

Used condom in last sexual intercourse (n = 59)	21 (35.6)

Had sexual intercourse when intoxicated (n = 59)	22 (37.3)


Characteristics	Number (%)

Age range (year)	6–88

Mean age (year) (SD)	42.5 ± 17.53

Length of stay (day) range	0–15

Mean length of stay (day) (SD)	8.3 ± 5.3

Length of stay (day)

 ≤1 week	67 (57.7)

 More than one week	21 (18.1)

Sex

 Male	63 (54.4)

 Female	53 (45.6)

Hospitalization

 Yes	87 (75)

 No	29 (25)

Nosocomial infection

 Yes	22 (18.9)

 No	94 (81.1)

MRSA	49 (42.2)

MSSA	67 (57.7)

PVL gene positive	25 (18.3)

MRSA carry PVL gene	14 (28.5)

MSSA carry PVL gene	11 (16.4)